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Summary
Despite the over 10-years’ experience providing pediatric antiretroviral therapy(ART)
and implementing different WHO guidelines, data on updated trends (after 2010) in advanced
disease at ART start, and on long-term survival of children receiving ART are scarce. Without
these data, the impact of recent WHO guidelines on early treatment initiation and long-term
survival remains unclear. First, we examined trends in advanced disease at ART start, then
described 10-year survival and investigated risk factors of early mortality in children treated with
ART and lastly examined the association between rapid ART initiation and outcomes (mortality
and loss to follow-up) of HIV infected.
We studied children (0-14 years) with HIV who initiated ART at seven Baylor
International Pediatric AIDS initiative supported clinics in Botswana, Lesotho, Malawi,
Swaziland, Tanzania, and Uganda. For the first aim, we conducted a pooled cross sectional study
of children (N=20,605) who initiated ART between 2003 and 2017. We examined the linear
trends in the proportion of children with advanced disease (over seven periods of ART initiation
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corresponding to WHO guideline implementation period) using the Cochran-Armitage test for
trend. For the second aim, we conducted a retrospective cohort study of children (N=18,010)
who initiated ART between 2003 and 2017. We estimated 10-year survival using the KaplanMeier approach and assessed risk factors of early mortality using Cox proportional hazard
regression. For the third aim, we conducted a retrospective cohort study of children (N=3,299)
who initiated ART between 2014 and 2017. We examined the association between rapid ART
initiation and outcomes of children using sub-distribution hazard regression for competing risks,
treating death and loss to follow-up as competing risks.
Between 2003-2017, the proportion of children initiating ART with advanced disease
declined among ages 5-9 years (58.3% to 39.9%; p<0.01) and 10-14 years (61.9% to 38.1%;
p<0.01), remained the same for ages <2 years (72.7% to 70.6%; p=0.1), and increased for ages 24 years (59.4% to 62.3%; p<0.01). 10-year survival probability %( 95%CI) was 88.9 (88.3-89.5)
overall, 83.7 (82.5-84.8) in children aged <2 years, 91.9 (90.7-93.0) in those 2-4 years, 92.6
(91.5-93.6) in 5-9 years and 88.8 (9 87.2-90.2) in 10-14 years. Half of the deaths occurred within
6–months of therapy. The risk factors of mortality were: baseline age <2 years (aHR 1.41(95%
CI: 1.11-1.79) compared to 10-14 years; WHO stage 4 (aHR 2.95(95% CI 2.33-2.72) and stage 3
(aHR 1.36(95% CI: 1.06-1.73) compared to stage 1 and 2 disease; severe (aHR=6.71, 95% CI
5.29-8.52) and moderate (aHR=2.64, 95% CI 1.90-3.66) immune suppression compared to
no/mild immune suppression; and severe underweight (aHR 1.84 (95% CI 1.48-2.29) compared
to normal weight-for-age. The risk of mortality was similar between children who initiated ART
on the same-day [adjusted sub distributional hazard risk (aSHR) =1.10, 95% CI 0.79, 1.75] and
those who initiated within 2-7 days (aSHR=1.05, 95% CI 0.77, 1.43) compared to those who
initiated within 8-90 days. The risk of LTFU was higher in children who initiated ART on the
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same day (aSHR=1.86, 95% CI 1.39, 2.49) and those who initiated within 2-7 days (aSHR=1.83,
95% CI 1.38, 2.43) compared to those who initiated within 8-90 days.
The proportion of children with HIV aged 5-14 years who initiate ART with advanced
disease has reduced, and long-term survival in those treated with ART is good. However, nearly
two-thirds of children aged <5 years are still initiating ART with advanced disease, early
mortality is high, and disease severity characteristics were associated with a higher risk of early
mortality. A significant proportion of those who initiate ART rapidly is lost to follow-up. While
programs can use the good survival outcome to motivate caretaker to test and initiate ART early
in children, more work is required to diagnose, initiate and keep children with HIV in care.
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BACKGROUND
INTRODUCTION
For nearly one and a half decades, combination antiretroviral therapy (ART) has been the
standard approach for treating pediatric HIV in the Eastern and Southern Africa region (ESA),
and it has improved short-term outcomes of HIV-infected children 1-4. Since the introduction of
ART, ESA countries have followed the World Health Organization (WHO) guidelines to provide
ART to HIV infected children. The WHO guidelines have continually changed to recommend
treating HIV infected children at a younger age, with less severe HIV disease, and with moreeffective first-line ART 5-9. These changes mean that over time children who start ART should be
younger, have less advanced disease and have better survival. Reports have shown declining
trends (up to 2010) in median age and proportion of children with advanced HIV disease 10-15.
Additionally, cohort studies have shown 1-2 year survival probability after ART of 80-90% 3, 4,
and losses to follow ranging from 2-39% 16, 17
Pediatric HIV treatment in resource-limited settings, however, continues to face
challenges, which can affect early HIV diagnosis in children and long-term outcomes (survival
and LTFU) of HIV infected children. These include limited access to virological tests for early
infant diagnosis and the continued need to adjust treatment ART doses as the child’s weight
increases. Moreover, children depend on caregivers to administer their medicines, and when they
become adolescents, they may not adhere to ART because of non-disclosure or treatment fatigue.
Poor adherence to ART could lead to treatment failure, disease progression, and death. Despite
these challenges of providing pediatric ART and the over 10-years’ experience providing
pediatric ART and implementing different WHO guidelines, data on updated trends (after 2010)
in baseline line characteristics, and on long-term survival and LTFU of children initiating ART
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are scarce. Without updated trends in baseline characteristics of children at ART initiation, the
impact of recent WHO guidelines on early treatment initiation remains unclear. Additionally, not
knowing long-term survival and LTFU of children on ART precludes our understanding of the
impact of ART programs on long-term survival in HIV infected children.
Our study aimed to examine temporal changes in baseline characteristics and to
investigate predictors and rates of long-term survival and loss to follow-up of HIV infected
children who start ART.

LITERATURE REVIEW
The Burden of pediatric HIV in Eastern and Southern Africa is high.
ESA carries the highest burden of total HIV infections, new HIV infections and HIVrelated morality in the world. In 2017, an estimated 66% (1.2 million of 1.8 million) of children
living with HIV worldwide were in ESA18, 19. Additionally, 51% (92,000 of 180,000) of new
pediatric infections were in ESA. The region has made significant progress identifying and
initiating HIV infected children on ART with currently 59% of children receiving ART
compared to a 52% global average 19. However, 47% (52,000 of 110,000) of all global pediatric
HIV deaths are in ESA and HIV is among the top 10 causes of death among children in this
region 20. In order to decrease pediatric HIV deaths, the ESA countries have adapted and
implemented the WHO pediatric HIV treatment guidelines.
Changes in the WHO guidelines for treating HIV infected children.
WHO HIV treatment guidelines consist of criteria of when to initiate ART in HIV
infected children and what ARV regimen to use. Since 2004, WHO has released five sets of
guidelines for treating HIV in children, each providing more simplified criteria than the one
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before (table 1). These guidelines have progressively recommended treating HIV-infected
children with less advanced disease, at a younger age, and with more effective first-line ART.
The first guidelines, released in 2004, provided WHO clinical stage criteria and agespecific immunological (CD4 cell count/percent) thresholds for starting ART in HIV infected
child (table 1). The second set of guidelines, released in 2006, recommended higher CD4
thresholds for starting ART than those in 2004. For example, the 2006 guidelines recommended
initiating ART in children aged <1 year at a CD4 threshold of <25% compared <20% in 2003.
The higher the CD4 count or percent, the less severe the disease is.
In 2010, after the children with HIV early antiretroviral (CHER) trial showed that early HIV
diagnosis and early ART reduced infant mortality by 76% and HIV progression by 75% 21, WHO
released a third set of guidelines. These guidelines recommended immediate ART for all HIV
infected children aged <2 years irrespective of WHO clinical stage or CD4 count and a higher
CD4 threshold for older children 6.
In 2013, the WHO then released the fourth set of guidelines recommending immediate
ART for all children aged <5yrs and again higher CD4 counts for older children 8. In 2015,
WHO dropped the clinical and immunological criteria and recommended immediate ART for all
children aged <15years irrespective of WHO clinical stage or CD4 cell count 9. Each set of
guidelines included treatment regimens as shown in table1. The changes in criteria for initiating
children on ART should be reflected in the baseline characteristics of children who initiate ART.
Additionally, in 2017, WHO recommended rapid ART initiation (initiating ART within seven
days upon diagnosis) in all people living with HIV including children.
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Table 1: Summary of the changes in WHO guidelines on when to initiate ART and the First-line ARV medicine
Guideline

Age

2003
CD4 <20%

2006
CD4<1500 or
<25%

CD4 <350
or <20%

CD4<750 or
<20%

<12 months

2010
Treat all irrespective of
CD4 or WHO stage

12-18months
18-24 month
Criteria for
initiating
ART*

First Line
ART regimen

24-35 month
36-59 month

CD4 <350
or <20%

5-14 years

CD4 <200
or <15%

NRTI 1

AZT or d4T

Treat all
irrespective
of CD4 or
WHO stage

CD4<750 or <25%

CD4 <350 or
<15%
CD4 <200 or
<15%
AZT or d4T
or ABC

CD4 count <350
AZT or ABC or D4T

NRTI 2

Third ARV

2013

CD4<500

2015

2017
Rapid
ART
initiation
(within
Treat all
irrespecti one week)
upon
ve of CD4
or WHO diagnosis
and
stage
medical
checks

<10yrs: ABC or AZT
≥10yr: TDF or AZT

3TC
NVP or EFV
( EFV only if >3yrs and
>10kg)

<2 yrs; exposed to
NVP: LPV/r
<2 yrs; not exposed to
NVP: NVP
2-3 yrs: NVP
≥3yrs: NVP or EFV

<3yrs: LPV/r
≥3 yrs: EFV

*For all the criteria, children with WHO clinical stage 3 or 4 HIV disease were eligible irrespective of age or CD4 cell criteria
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Temporal trends in baseline characteristics of children at ART initiation.
Characteristics of children like age, WHO clinical stage, CD4 count and Weight for Age
Z-score at diagnosis, entry into care and at ART initiation are measures indicating the duration of
HIV disease. Characteristics at diagnosis and entry are a measure of early HIV diagnosis, while
characteristics at ART initiation are a measure of early ART initiation. Early diagnosis and Early
ART initiation mean children should be diagnosed and started on treatment at a young age and
without advanced disease(WHO stage 1 or 2) or severe disease( CD4 count > 200 cells/mm3).
Early HIV diagnosis and Early ART initiation are critical to stop rapid disease progression in
children and reduce mortality in HIV infected children. Measuring trends in these characteristics,
therefore, provides a measure of progress towards early HIV diagnosis and early ART initiation
in HIV-infected children, a major goal of the WHO guidelines. Studies have examined trends in
baseline characteristics up to 2010, but the trends after 2010 are scarce.
Temporal trends in baseline characteristics of children starting ART up to 2010.
Up to 2010, there were decreasing trends in the median age and proportion of children
with advanced HIV disease (WHO clinical stage 3 or 4) at ART start. However, a substantial
proportion of children started ART when they were older or with advanced HIV disease.
Moreover, the trends in the proportion of children who are underweight at ART start are
inconclusive.
Studies that have examined trends in baseline characteristics of HIV infected children
who started ART up to 2010 show decreasing median age and proportion of children with
advanced HIV disease 10-15. However, in 2009/2010 the median age at the start of ART was still
high (range 3 -8 years) and half of the children started ART when they had advanced HIV
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disease. Moreover, up to 80% of the children under five years of age had advanced HIV disease
when they started ART 13.
In addition, studies that measured trends in the proportion of children who are
underweight at ART start showed conflicting results. For example, a study using the
International Epidemiology Databases to Evaluate AIDS (IeDEA) in five countries in Southern
African showed a significant decrease in the proportion of children with moderate/severe
underweight from 31% to 28% 13. However, a study in South Africa 11, and another in three
countries in East Africa 10 showed no change in the trend.
Young age, advanced HIV disease, and moderate or severe malnutrition are associated
with higher mortality in HIV infected children 1, 3, 10, 22-26. The trends in these baseline
characteristics could have changed after 2010 because of the changes in WHO guidelines;
however, data on the trends after 2010 are limited.
Data on temporal trends in baseline characteristics of HIV infected children starting ART
beyond 2010 are limited.
Although most changes in WHO guidelines for treating HIV in children occurred after
2010, few studies examine temporal trends in baseline characteristics of HIV infected children
initiating ART beyond 2010, and they show mixed results. For example, in the IeDEA cohort
study of HIV infected children started on ART in three Central African countries (Burundi,
Democratic Republic of Congo and Rwanda), the proportion of children with advanced HIV
disease decreased from 55% in 2004/2005 to 42% in 2012/201312. In contrast, in a cohort study
in Tanzania, the proportion of children with advanced HIV disease increased from 46% in
2005/2007 to 76% in 2013/201427. Moreover, while in the IeDEA cohort in Central Africa, the
proportion of children with severe malnutrition decreased from 41% in 2004/2005 to 17% in
2002/201312, in another cohort study in Tanzania the proportion increased from 26% in 200819

2012 to 62% in 2013/2014 28. Conversely, all three studies found a decreasing trend in the
median age at ART initiation from 7yrs to 5.8 years in Central Africa, and 6yrs to 4 years in
Tanzania 12, 27, 28.
These differences in the proportion of children with advanced disease and severe
malnutrition may reflect variations in programmatic strategies in implementing guidelines. For
example, in Tanzania, the program implemented active case finding in in-patient wards, which
resulted in a higher yield of children with advanced disease. While in central Africa, there was
expanded early infant diagnosis and the proportion of children identified with less advanced
disease increased. Notably, in all of the above studies, the median age (4 -5.8yrs), and proportion
of children with advanced disease (42-76%) or severe malnutrition (17-62%) in the last year of
the study was high.
The inconclusive trends after 2010 highlight the need for more studies to examine
updated trends in baseline characteristics of children starting ART. Knowing the updated trends
improves our understanding of the impact of more recent WHO guidelines on early treatment
initiation. Further, we can examine progress towards early diagnosis and early ART initiation.
Early HIV diagnosis and early ART initiation reduce disease progression and mortality in HIVinfected children 21.
Survival among HIV infected children initiated on ART
Studies using routine ART program data in resource-limited settings (RLS) show
variability in survival of HIV infected but most have short follow-up periods (1-2 years).
However, data on long-term survival in RLS are scarce. Most data on long-term survival are
from high-income countries, and most are cohorts of older children. Challenges of providing
pediatric ART in high income and RLS differ. Therefore examining long-term survival and
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predictors of mortality in RLS improves our understanding of the success of long-term ART in
those settings and identifies opportunities for improvement.
Short-term survival of HIV infected children initiating ART
In RLS, cohorts studies using routine ART program report mortality of 4.3-29% 1, 11, 23, 29,
mortality rates of 1- 6.9/100 person years 2, 10, 15, 22, 25, 30, 31, and survival probability of 90% in
children on ART 4. Most of these studies have follow up time of one-two years. The short
follow-up time could be because the studies were earlier in the ART program before the children
accrued longer follow-up time or by design. HIV, however, is a chronic disease and its treatment
is life-long. In RLS, lifelong ART presents challenges that could affect the success of ART and
long-term survival. For example, additional challenges in RLS may include that health care
workers need to continually adjust treatment doses to the child’s weight yet follow-up may be
difficult/inconsistent, appropriate pediatric formulations may be lacking, there are high losses to
follow-up, and there may be ARV stock-outs. Moreover, children are vulnerable because they
depend on caregivers-who may be too sick to administer their medicines and as they grow into
adolescents, they may not adhere to treatment because of non-disclosure of HIV status or
treatment fatigue. All these challenges could lead to poor long-term adherence to ART, which
can result in treatment failure, disease progression and death. Despite these challenges, data on
long-term survival on ART in RLS are scarce.
Data on long-term survival of HIV infected children initiating ART in RLS are scarce
Studies examining long-term survival in HIV infected children receiving ART have
mainly been from high and middle-income countries. These studies report 5-10 year mortality
rate of 1.2-1.7 per 100 person-years and survival of >94-99% 32-36. Few studies that report longterm mortality in RLS show 3-4 yr mortality of 3.6-7.7% among all children 3, 15 and 16% in
infants 24, and survival of 81%3. More recent report show 8-years survival of 90% in
21

Mozambique 37 and about 89% in Zambia38 .Most of the studies reporting long-term survival are
among older children (median age 3.5-7 years). These studies do not examine age-specific longterm survival and yet long-term survival may differ by age because in studies with short-term
follow-up, the risk of death is higher in younger children than older children 1, 3, 10, 22-26.
Given the challenges of long-term ART and the scarcity of data on long-term survival in
HIV infected children and more so age-specific survival in RLS, there is a need to fill this
knowledge gap. Examining long-term survival would improve our understanding of the success
of long-term ART and identify opportunities for improvement.
Risk factors of mortality in HIV infected children receiving ART
Risk factors for death in HIV infected children receiving ART are well documented but risk
factors of early and late death are not been described. Young age (<2yrs), advanced disease
(WHO stage 3 and 4), severe immune suppression (CD4 <200 cell/mm3 in children ≥5yrs or
CD4percentage <15% in children <5yrs), severe malnutrition and TB disease have been
associated with a high risk of death 1, 3, 10, 22-25, 30, 37. However, most of these studies modeled the
variables as fixed covariates and did not examine the risk factors of early (<6 months) and late
mortality (≥ 6months) independently,yet, 50-60% of mortality in HIV infected children who
initiate ART is within the first six months 30, 33, 39, and predictors of early (<6 months) and late
mortality (≥6 months) may differ 33. For example, a cohort study of HIV infected children
receiving ART in Europe showed that although baseline age and advanced disease were risk
factors for early death and not late death, time-updated BMI and severe immune suppression
were risk factors for late death 33. Examining predictors of late and early death in RLS is
important because of the difference in infectious disease burden and quality of care between
high-income countries and RLS.
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Rapid ART initiation in children living with HIV
In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) set ambitious
targets described as “95-95-95” targets to end AIDS by 203040. These targets are that 95% of
people living with HIV know their HIV status, 95% of those diagnosed with HIV initiate and
sustain ART and 95% of those on ART achieve and maintain viral suppression. To attain these
targets, children diagnosed with HIV must be linked to HIV care, promptly initiated on ART and
retained in care. However, 20% of children with HIV are lost to follow up between diagnosis and
ART initiation 41. After initiating ART mortality ranges from 4.3-29% 1, 11, 23, 29 and loss to
follow-up( LTFU) ranges from 2-39% 10, 16, 17, 28, 29. These high losses to follow-up and mortality
if not addressed can preclude attainment of the 95-95-95 goals for children by 2035.
As a strategy to reduce loss to follow-up and mortality in people living with HIV, the
World Health Organization in 2017 recommended initiating ART in all people with HIV within
7-days (including same-day initiation in people who are ready) upon diagnosis.42. This
recommendation, also called rapid ART initiation, followed trial reports in adults showing rapid
ART initiation was associated with an increased likelihood of starting ART, reduced mortality,
and better viral suppression and retention in care as compared to delayed initiation 42-45.
Although the WHO recommended rapid ART initiation in children as well, data on the
effect of rapid ART initiation on outcomes of children were limited and inconclusive. Two trial
conducted among hospitalized children showed no difference in mortality in children who
initiated ART rapidly versus those on delayed initiation46, an observational study in Malawi
showed improved outcomes in children with uncomplicated malnutrition 47. None of these
studies examine if rapid ART initiation is associated with loss to follow-up, Yet observational
studies in adults show an increased risk of being lost to follow-up after rapid ART initiation
compared to delayed ART initiation 48, 49. Given the paucity of data on this topic in children,
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further research is required to investigate the effect of rapid ART initiation on the outcomes of
children.

PUBLIC HEALTH SIGNIFICANCE
This study will show trends in advanced in children starting ART in ESA over 15 years
(2003-2017). Second, we will describe rates and predictors of long-term survival and report the
association between rapid ART initiation and outcomes of children treated with ART. These
outcomes will have a positive impact because they improve our understanding of how changes in
the WHO guidelines over time have affected early treatment initiation and survival of HIV
infected children. Further, this information could be used for health care planning and
intervention development at clinic and government levels. For example, knowledge of predictors
of mortality and LTFU will inform the development of interventions to improve survival and
retention in care. Also, long-term survival rates could be used to model pediatric HIV
epidemiological estimates and life expectancy in HIV infected children, and to guide patient
decisions and patient education. Findings of the association between rapid ART initiation and
outcomes of children may be used to inform future revisions of rapid ART initiation guidelines
in children. Finally, these data provide a benchmark against which future intervention and
guidelines will be measured.

SPECIFIC AIMS
Introduction of ART has led to a reduction in short-term mortality in children 1-4.
However, pediatric HIV diagnosis and treatment in RLS continues to be challenging because of
limited access to virological tests for early infant diagnosis, the need for pediatric friendly ARV
medicines and need for health care providers to continually adjust ARV doses to the child’s
weight. Even after starting ART, children continue to be vulnerable because they depend on
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caregivers to administer their medicines, and when they become adolescents, they may not
adhere to ART because of non-disclosure or treatment fatigue. Poor adherence to ART could
lead to treatment failure, disease progression, and death, thus affecting long-term outcomes
(survival and LTFU) in children. To improve outcomes of HIV infected children, WHO
guidelines for treating children with HIV have changed over time to recommend treating HIV
infected children at a younger age, with less severe HIV disease, and with more-effective firstline ART and more recently to initiate ART within seven days from diagnosis 5-9, 42. These
changes mean that over time children who start ART should be younger, have less advanced
disease and have better survival.
Despite the challenges of providing pediatric ART, the over 10-years’ experience
providing pediatric ART and implementing different WHO guidelines, data on updated trends
(after 2010) in baseline line characteristics, and on long-term survival and LTFU of children
initiating ART are scarce. In addition, evidence of the effect of rapid ART initiation on outcomes
of children with HIV is limited and inconclusive. Without updated trends in baseline
characteristics of children at ART initiation, the impact of recent WHO guidelines on early
treatment initiation remains unclear. Additionally, not knowing long-term survival and LTFU of
children on ART precludes our understanding of the impact of ART programs on long-term
survival in HIV infected children. Lastly, the lack of evidence of the impact of rapid ART
initiation limits the uptake of this recommendation.
The overall objective, of this proposal, is therefore to examine trends in advanced HIV disease
and to investigate predictors and incidence of mortality and LTFU children who start ART in
ESA. The specific aims of this proposal are:
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Aim 1: Examine trends in advanced HIV disease at ART initiation among children
initiated on ART between 2003-2017 in ESA.
Hypothesis 1a: we hypothesize that the proportion of children with advanced disease at
ART initiation will reduce with an increasing calendar year of ART initiation.

Aim 2: Investigate the incidence and predictors of all-cause mortality in HIV infected
children starting ART during 2003-2017 in ESA.
2a. Investigate 10-year survival probability in HIV infected children initiating ART during
2006-2017 in ESA.
2b. Identify risk factors of early mortality in HIV infected children starting ART during
2006-2017 in ESA.
Aim 3: Investigate the association between rapid ART initiation and outcomes (mortality and
loss to follow-up) of children with HIV who initiated ART between 2014 and 2017 in ESA
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METHODS
STUDY SETTING
This study was conducted using data from the Baylor International Paediatric AIDS
Initiative (BIPAI) network clinics in Botswana, Malawi, Swaziland, Lesotho, Tanzania, and
Uganda. BIPAI, one of the first organizations to provide pediatric HIV care in Africa, started these
network clinics in partnership with national governments 50. The first clinics were started in 2003
in Botswana and Uganda. Other clinics were started in Malawi in 2004, in Lesotho and Swaziland
2005 and Tanzania in 2010. The HIV infected children in these clinics are treated following
country-specific guidelines, which are adapted from WHO guidelines. These children have
scheduled visits at least three monthly, and data at all clinics are recoded using the same electronic
medical record (EMR) system. Altogether, these clinics have enrolled and initiated a cohort of
over 30,000 HIV infected children on ART. This cohort of children provides an opportunity to
examine trends in baseline characteristics and long-term outcomes of HIV infected children.

DATA COLLECTION
Individual patient data from routine clinic visits were pooled electronically de-identified
and sent to the study team for cleaning. A data query was developed and used to extract the
required variables (table 3). Extracted data was exported to a CSV file. New patient identifiers
(ID) were assigned to each participant and unique identifiers removed. Only date of birth and
date of enrolment in the clinic were maintained for computing time to event for data analyses.
The BIPAI data administrator extracted and de-identified the data, retained the link between
unique identifiers and new ID’s and shared the data de-identified data with the research team for
cleaning and analysis.

27

AIM SPECIFIC METHODS
Methods for specific aim 1:
Aim 1a: Examine trends in advanced HIV disease at ART initiation among children initiated on
ART between 2003-2017 in ESA.
Study design
We conducted a pooled cross sectional study and trend analysis of baseline characteristics of
cohorts of children who initiated ART between 2003 and 2017. The cohorts of children were
grouped into seven calendar periods based on the year of ART initiation. The periods also
correspond to the WHO guideline periods.
Study participants
We included all ART-naïve children with HIV aged <15 years who initiated ART between
1 January 2003 and 31 December 2017 at the COEs. Additionally, children exposed to
antiretroviral prophylaxis for preventing mother to child HIV transmission were included.
Variables and definitions
The baseline variables at ART initiation included age, sex, weight, entry point to care, WHO
clinical stage and CD4 count, CD4 percent, weight-for-age z-scores (WAZ). The entry points to
care were the prevention of mother to child HIV transmission(PMTCT) clinic, inpatient ward/TB
clinic(IPD/TB), outpatient department(OPD), voluntary counseling and testing(VCT), and
referrals from other health facilities and outreaches(Others). WHO clinical stage and CD4 were
considered to be “at ART initiation” if they were taken on or at a date closest to the ART
initiation date within a window of 6-months before until 1-month after ART initiation. Weight
were those taken ± 1months of ART initiation. WAZ for children aged < 10 years were
computed using the WHO child growth standards 51, 52 and for children aged 10-14 years, the
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Centers for Diseases control and prevention (CDC) growth standards were used53. The CDC
growth standards were used for children ≥ 10 years because the WAZ scores were not available
in the WHO child growth standards. Advanced HIV disease was defined as having WHO clinical
stage III or IV disease and/or severe immune suppression for age (CD4% < 25% for children <1
year of age, <20% for children aged 1-3yrs, < 15% for children 3-5 years and <15% or CD4
count <200 cell/mm3 for children aged 5-14 years)42, 54.
The years of ART initiation were grouped into seven calendar periods: 2003-2005, 20062007, 2008-2009, 2010-2011, 2012-2013, 2014-2015, and 2016-2017 as a proxy for when WHO
guidelines were implemented. The period 2003-2005 is when the 2003 guidelines were
implemented; 2006-2007 and 2008-2009 represent the 2006 guidelines period; 2010-2011 and
2012-2013 represent the 2010 guidelines period; 2014-2015 represents the 2013 guidelines
period, and 2016-2017 represents the 2015 guidelines period.
Power calculation
We estimated the power to detect a significant (p<0.05) linear trend in categorical variables
using the Cochrane-Armitage trend test and trend in continuous variables using. The data
categorized into seven groups corresponding to the period of enrolment in care and of ART
initiation: 2003-2005, 2006-2007, 2008-2009, 2010-2011, 2012-2013, 2014-2015, 2016-2017.
The total sample size is 25,000 HIV infected children, and the smallest group had 2000 HIV
infected children. To estimate power, we used proportions and medians from previous trend
studies from central Africa 12 and in southern African 13 and varied the sample size in each group
between 500 and 5000. Power estimates from the proportions and medians from each study were
plotted in separate graphs. The graphs plotted using the data from central African study were
labeled (a) and those using the southern African study were labeled (b). A minimum sample
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size of 800 in each group had 80% power to detect a significant linear trend in each variable (fig
2a). Since our data has at least 2000 children in each group, the study will have sufficient power
to detect linear trends in all the baseline characteristics over time.
Figure 1: Estimated power for trend test for (a) the proportion with WHO stage 3 or 4 disease,
(b) proportion with severe immune suppression

Data analysis
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We summarized characteristics at ART initiations using medians (interquartile ranges [IQR]) and
proportions for continuous and categorical variables respectively. The characteristics at ART
initiation were analyzed by calendar period of ART initiation. Trends in categorical and
continuous characteristics over the ordered calendar periods were assessed using the CochranArmitage test and Cuzick’s test for trend respectively. We examined overall trends in advanced
disease as well as by age-specific (<2 years, 2-4 years, 5-9 years and 10-14 yrs.) and countryspecific trends.

Methods for specific aim 2
Aim 2: To investigate the incidence and predictors of all-cause mortality in HIV infected
children starting ART during 2003-2017 in ESA.
Study design, and population
This was a retrospective cohort study using patient-level data pooled from seven BIPAI
COEs in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda. We included children
with HIV aged <15 years who initiated ART between January 2006 and June 2017 and had two
or more follow-up visits after ART initiation. Children who were ARV experienced (except for
exposure to ARVs for PMTCT) at entry into care were excluded. The cohort start date for
Tanzania was 2010, corresponding to the period when the clinic became operational.
Study variables and definitions
The independent study variables were age, sex, country, weight, height, WHO clinical
stage, CD4 count, CD4 percent, weight for age Z-scores (WAZ), BMI for age Z scores (BAZ),
ART regimens, TB diagnosis, hemoglobin levels(Hb) and immune suppression level. The child’s
weight or height was considered to be at ART start if they were taken ± 1month from the ART
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start date, while WHO stage and CD4 count or percent at ART start were taken on or at a date
closest to the ART initiation date within six months before and one month after ART initiation.
We computed the WAZ for children aged < 10 years and BAZ for all children using the WHO
child growth standards 51, 52. WAZ for children aged 10-14 years using the Centers for Diseases
Control and Prevention (CDC) growth standards 53 because this measure was not available for
the age group in the WHO growth standards. CD4 counts or CD4 percentage were categorized
into immune suppression levels (no/mild, moderate or severe) for age according to the WHO
classification 42, 54. The calendar period of ART initiation was categorized into three, 4-year
periods: 2006-2009, 2010-2013 and 2014-2017 corresponding to WHO guideline periods; 20142017 covered two guideline periods.
The main outcome variable was all-cause mortality and was defined as death from any
cause including HIV related and non-HIV related deaths. The date of death was extracted from
the EMR. If the date was missing, we used the date the chart was closed. Other events that were
censored in the analysis were lost to follow-up (LTFU), transfer out and active in care. The
patient was considered LTFU if there was a gap of 90 days between their next clinic appointment
and the database closure date (December 31, 2017). The date of LTFU was the chart closure
date, and if the chart was not closed, the patient was censored 90 days after the last scheduled
appointment. The patient was considered transferred-out if the transfer was documented and the
date of transfer was that recorded in the chart.
Statistical analysis
Patient characteristics at ART initiation were described using summary statistics
(medians and proportions) by age groups (<2 years, 2-4 years, 5-9 years and 10-14 years). We
computed overall mortality rates per 100 person-years (PY) and rates within the first six months
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of ART, at 6-24 months and after 24 months. Kaplan-Meier estimates for 10-year survival
probability was calculated overall, by age group, country, and calendar period of ART initiation;
differences in survival curves were tested using the log-rank test. Time to death was computed
from the date of ART initiation, and children were right-censored at the earliest of either LTFU,
transfer out, 10-years of follow-up or database closure date. We examined risk factors of
mortality in the first 6-months and 6-24 months on ART using univariable and multivariable Cox
proportional hazard regression models. We limited the analysis to the first 24 months to enable
us to examine the effect of the most recent WHO- treatment guidelines (2014-2017) on survival.
We used a stepwise regression method to select the most parsimonious model. The criteria for a
variable to enter and to stay in the model were p≤0.15 and p≤0.05, respectively. Known
predictors of death, including WHO clinical stage, immune suppression level, and age were
purposefully included in the analysis. We tested the proportional hazards assumption using the
Schoenfield test. To avoid loss of information and biased estimates because of missing data, we
imputed missing CD4, WHO stage, WAZ, and Hb values using multiple imputation by chained
equations (MICE), using 20 cycles55, 56. We conducted sensitivity analyses using complete case
analysis and competing risks analyses with LTFU as the competing risk.

Methods for Specific Aim 3
Aim 3: Investigate the association between rapid ART initiation and outcomes (mortality and
loss to follow-up) of children with HIV who initiated ART between 2014 and 2017 in ESA.
Study design
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We conducted a retrospective cohort study using electronic medical records of children
with HIV who initiated ART at seven BIPAI COEs in Botswana, Eswatini, Lesotho, Malawi,
Tanzania, and Uganda.
Study participants
We included ART_naive HIV-infected children aged <15 years who entered HIV care at
the study sites between January 2014 and 2017, and initiated ART within 90 days of enrolment.
The 90 days was the median time to ART initiation observed among patients diagnosed at
enrolment in a global study of access to ART in children 41. However, we also assumed that if
children were eligible at enrolment, ART should be initiated at most within 90-days. We
excluded children who initiated ART less than 6-months from the database closure date
(December 31, 2017).
Variables and definitions
Exposure: The exposure was rapid ART initiation, which we defined as initiating ART within 7days of enrollment into care 42. We categorized rapid initiation into same-day initiation and
initiation within 2-7 days. The comparison group was those who initiated ART within 8-90 days
(delayed initiation).
Outcome: The outcomes of the study, were all-cause mortality and LTFU. LTFU, defined as
having a gap of 90 days between the next clinic appointment and the database closure date
(December 31, 2017). The date of LTFU was the chart closure date, and if the chart was not
closed, the patient was censored 90 days after the last scheduled appointment. The other
outcomes were death, transfer out and active in care. The date of death and of transfer out were
the dates recorded in the EMR, and if missing, the chat closure date was used. Children were
considered active in care if none of the other outcomes had occurred and they were assigned the
date of the last visit as the outcome date.
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Other covariates: Other covariates considered were age, sex, country World Bank income
category(middle income vs. low income), weight for age Z-scores (WAZ), TB diagnosis, WHO
clinical disease stage (WHO stage) and immune suppression level and period of initiation(20142015 versus 2015-2016). The WAZ was computed from the weight taken on the ART start date.
If weights were missing, weight taken ± 1month from ART start date was used. WAZ for
children aged < 10 years were computed using the WHO child growth standards 51, 52 and for
children 10-14 years using the Centers for Diseases Control and Prevention (CDC) growth
standards 53. The CDC growth standards were used for children age 10-14 years because this
measure was not available in the WHO growth standards. CD4 counts or CD4 percentage cut
were categorized into immune suppression level (no/mild, moderate or severe) for age according
to the WHO classification 42, 54. The year of initiation was categorized as 2014-2015 and 20162017.
Data analysis
Baseline characteristics at ART initiations were summarized using frequencies and proportions,
and medians and interquartile ranges (IQR), stratified by the timing of ART initiation. We
estimated the 24-month cumulative incidence of death and LTFU by time to ART initiation using
competing risks survival analysis. Death and LTFU were considered competing risks. Persontime accrued from the ART initiation date to the earliest of LTFU, death, transfer out, 24 months
of follow-up or the database closure date (December 31, 2017). We assessed the association
between rapid ART initiation and 24-months’ mortality and LTFU using sub-distribution hazard
regression analysis for competing risks adjusting for confounders. Confounders were selected
using stepwise regression using setting the criteria for a variable to enter and stay in the model at
p=0.15 and p=0.05, respectively. Known risk factors of loss to follow-up were purposefully
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included. Conducted a sensitivity analysis excluding the patients who had only one recorded
visit. We also conducted stratified analysis to explore if age modified the association between
rapid ART initiation and the outcomes. We imputed missing CD4, WHO clinical stage, WAZ,
and hemoglobin values using multiple imputation by chained equations (MICE), using 20 cycles
55, 56

.

HUMAN SUBJECTS, ANIMAL SUBJECTS, OR SAFETY CONSIDERATIONS
This study was approved by country-specific institutional review boards, Baylor College of
Medicine IRB and University of Texas Health Science Center at Houston Committee for the
protection of human subjects.
Confidentiality:
The de-identified data were received from BIPAI and stored in a password-protected computer
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ABSTRACT
Introduction
The aim of this study was to examine age- and site-specific trends in advanced HIV disease at
ART initiation among HIV-infected children. We also examined trends in age and time-to-ARTinitiation.
Methods
We analyzed records of HIV-infected children (0-14 years) who initiated ART between 20032017 at seven Baylor International Pediatric AIDS Initiative clinics in 6-African countries.
Advanced HIV disease was defined as having WHO stage III or IV disease and/or severe
immune suppression for age according to WHO criteria. Time-to-ART-initiation was measured
from date of entry into care. We analyzed trends in categorical and continuous variables over
seven calendar periods from 2003 to 2017 using Cochran-Armitage and Cuzick’s test for trend
respectively.
Results
20,605 children (31.6% aged <2 years, 20.2% 2-4 years, 26.6% 5-9 years and 21.6% 10-14
years) were included. Half were girls, 33% were from Uganda, 19.8% from Malawi, 13.9% from
Lesotho, 13.3% from Tanzania, 10.8% from Eswatini and 9.2% from Botswana. Between 20032017, the proportion of children initiating ART with advanced disease declined among ages 5-9
years (58.3% to 39.9%; p<0.01) and 10-14 years (61.9% to 38.1%; p<0.01), remained the same
for ages <2 years (72.7% to 70.6%; p=0.1), and increased for ages 2-4 years (59.4% to 62.3%;
p<0.01). By site, the proportion decreased in Eswatini (69% to 33%), Lesotho (80% to 34%),
Malawi (94% to 33%), and Tanzania (71% to 69%) (all p<0.01), remained the same in Botswana
(70% to 52%, p=0.06) and increased in Uganda (46% to 65%; p<0.01).

38

The median age(IQR) in years at ART initiation increased in Botswana [5.1 (2.2-8.1) to 9.6
(1.5-12.6)], Eswatini [4.3 (1.6-8.1) to 8.5 (1.7-11.7]; Lesotho [3.9 (1.4-7.9) to 8.4 (2.8-11.5)] and
Malawi [5.4 (2.2 to 8.5) to 6.6 (1.9-10.8)] (all p’s<0.01), remained the same in Tanzania [4.2
(1.5-9.5) to 3.3 (1.4-8.9) ; p=0.1] and declined in Uganda [6.7 (3.8-10.6) to 2.1 (0.8-6.2);
p<0.01]. Time-to-ART-initiation reduced among all children [median (IQR):63 (28 to 184) to 5
(0 to 22) days].
Conclusion
Between 2003-2017, disease severity at ART initiation declined among children aged 5-14 years,
remained the same in children <2 years, and increased in those aged 2-4 years. Over time,
children initiating ART in southern Africa sites were older and less severely ill; those in Eastern
Africa sites were younger and more severely ill. In 2016-2017, children initiated ART within the
first week in care, but a substantial proportion did so with advanced disease. More efforts are
required to diagnose and initiate children on ART early.
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INTRODUCTION
In 2017, an estimated 1.8 million children aged<15 years were living with HIV globally,
66% of them in Eastern and Southern Africa (ESA)1. Although ESA bears the highest burden of
pediatric HIV, the region has made significant progress initiating children with HIV on
antiretroviral therapy (ART). In 2017, 59% of children with HIV in the region were receiving
ART compared to 52% globally1. ART improves survival in children 2-5; however, disease
severity at therapy start is an important prognostic factor. Compared with children with less
advanced disease, those who start ART with advanced disease have a higher risk of death2, 4, 6-11.
To maximize the benefits of ART in children with HIV, the World Health Organization
(WHO) provided five sets of normative guidelines on when to initiate ART in children and
adolescents between 2003 and 201712-15. With more evidence of the benefits of early therapy in
children and better treatment regimens, each updated version of the guidelines expanded
treatment initiation criteria to include children with less advanced disease (table 1). The most
recent guideline (2015) recommends immediate ART upon diagnosis in all children under 15
years of age. Altogether, the evolution of these guidelines mean that over time children who start
ART should have less advanced disease.
Previous studies examining trends in characteristics of children with HIV initiating ART
in sub-Saharan African found that, although age and the proportion with advanced disease were
declining, a substantial proportion of children still initiated ART with advanced disease6, 16-20.
Most of these studies examined trends in characteristics up to 2010. Those that examine trends
beyond 2010, a period when WHO guidelines for ART initiation have changed most, are few17,
21

. Moreover, data on age-specific trends are scarce; yet, until 2015, WHO recommended

different treatment initiation guidelines by age group (Table 1). Examining trends beyond 2010
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will improve our understanding of the impact of more recent WHO guidelines on early treatment
initiation. Furthermore, examining age-specific trends may highlight the differential impact of
the WHO guidelines on early treatment initiation by age group and identify opportunities to
improve early treatment initiation. The objective of our study was to examine age- and sitespecific trends in advanced HIV disease among children with HIV who initiated ART in Eastern
and Southern Africa between 2003 to 2017. We also examined trends age at ART initiation and
overall time-to-ART-initiation.
Table 1: The changes in the WHO recommended criteria for initiating ART in children

Guideline

Age
<12 months

Criteria for
initiating
ART*

1218months
18-24
month
24-35
month
36-59
month
5-14 years

2003
CD4
<20%
CD4 <350
or <20%
CD4 <350
or <20%
CD4 <200
or <15%

2006
CD4<1500
or
<25%

CD4<750
or <20%

CD4 <350
or <15%
CD4 <200
or <15%

2010
Treat all
irrespective of
CD4 or WHO
stage

2013

Treat all
irrespective of
CD4 or WHO
stage

CD4<750 or
<25%
CD4 count
<350

2015

Treat all
irrespective of
CD4 or WHO
stage

CD4<500

*For all the criteria, children with WHO clinical stage 3 or 4 HIV disease were eligible irrespective of age or CD4 cell
criteria

METHODS
Study design, setting, and participants
We conducted a pooled cross sectional study and trend analysis of the proportional of
children with advanced HIV disease at ART initiation and time to ART initiation in seven
cohorts of children with HIV who initiated ART between 2003-2017. The cohorts were defined
by the calendar periods of ART initiation (2003-2005, 2006-2007, 2008-2009, 2010-2011, 2012-
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2013, 2014-2015, and 2016-2017 which are a proxy for when WHO guidelines were
implemented in the study sites.
The children were from seven Baylor International Paediatric AIDS Initiative (BIPAI)
centers of excellence (COE’s) in six countries in Eastern and Southern Africa (Botswana,
Eswatini, Lesotho, Malawi, Tanzania, and Uganda). BIPAI started each COE in partnership with
the host governments. The first clinics were started in 2003 in Botswana and Uganda, and later in
2004 in Malawi, 2006 in Lesotho and Swaziland and 2010 in Tanzania (2 COE’S). These COEs
provide free HIV prevention, care, and treatment services in line with country-specific guidelines
that are adapted from WHO guidelines, and they use a standardized electronic medical records
system.
We included all ART-naïve children with HIV aged <15 years who initiated ART between
1 January 2003 and 31 December 2017 at the COEs. Additionally, children exposed to
antiretroviral prophylaxis for preventing mother to child HIV transmission were included. The
data were de-identified from routine patient management records, which were extracted and pooled
electronically.
Variables and definitions
The baseline variables at ART initiation included age, sex, weight, entry point to care,
WHO clinical stage and CD4 count, CD4 percent, and weight-for-age z-scores (WAZ). The entry
point to care were the prevention of mother to child HIV transmission(PMTCT) clinic, inpatient
ward/TB clinic(IPD/TB), outpatient department(OPD), voluntary counseling and testing(VCT),
and referrals from other health facilities and outreaches(Others). WHO clinical stage and CD4
were considered to be “at ART initiation” if they were taken on or at a date closest to the ART
initiation date within a window of 6-months before until 1-month after ART initiation. Weight
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were those taken ± 1months of ART initiation. WAZ for children aged < 10 years were
computed using the WHO child growth standards22, 23 and for children aged 10-14 years, the
Centers for Diseases control and prevention (CDC) growth standards were used24. The CDC
growth standards were used for children ≥ 10 years because the WAZ scores were not available
in the WHO child growth standards.
Advanced HIV disease was defined as having WHO clinical stage III or IV disease
and/or severe immune suppression for age (CD4% < 25% for children <1 year of age, <20% for
children aged 1-3yrs, < 15% for children 3-5 years and <15% or CD4 count <200 cell/mm3 for
children aged 5-14 years)25, 26.Time to ART initiation was computed from the date of entry into
care to the date of ART initiation. The dates of entry into care were grouped into similar calendar
periods as the years of ART initiation.
Data analysis
We summarized characteristics at ART initiations using medians (interquartile ranges
[IQR]) and proportions for continuous and categorical variables respectively. The characteristics
at ART initiation were analyzed by calendar period of ART initiation. Trends in proportions of
children with advanced disease and Trends in time to ART initiation over the ordered calendar
periods were assessed using Cochran-Armitage test and Cuzick’s test for trend respectively. We
examined trends in advanced HIV disease overall, by age-group (<2 years, 2-4 years, 5-9 years
and 10-14 yrs.) and country. The data from two sites in Tanzania were combined.
Ethical approval
This study was approved by country-specific institutional review boards, Baylor College of
Medicine IRB and University of Texas Health Science Center at Houston Committee for the
protection of human subjects.
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RESULT
Between 2003 and 2017, 20,605 ART-naïve children initiated ART in seven BIPAI
COEs in the six African countries and were included in the analysis. Table 2 shows the
characteristics and entry points to care for all children by country. The largest number of children
were initiated in Uganda (33%), followed by Malawi (19.8%), Lesotho (13.9%), and Tanzania’s
2 COE’s (13.3%), Eswatini (10.8%) and Botswana (9.2%). The median (IQR) age at ART
initiation was 4.7 (1.6 to 9.3) years, range across COEs 3.6 to 5.7 years. The proportion of boys
and girls was similar overall and across COEs. The number of children initiating ART increased
from 1,920 in 2003-2005, peaked at 3,861 in 2010-11 and declined after that to 2,018 in 2016-17
(Supplementary Table 1). The changes in the number of children initiating ART were similar in
all countries. The median (IQR) time from enrollment to ART initiation decreased from a peak
of 63 (28 to 184) days in 2008-2009 to 5 (0 to 22) days in 2016-2017, p<0.01 (Supplementary
Table 1).
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Table 2: Characteristics at antiretroviral therapy initiation of children with HIV from 6 countries in Eastern and Southern Africa by
calendar period of ART initiation: 2003-2017
Overall
N=20,605
4.7
(1.5 to 9.3)

Botswana
N=1893
5.7
(1.6 to 10)

Eswatini
N=2222
4.9
(1.5 to 9.4)

Lesotho
N=2870
5.1
(1.4 to 9.7)

Malawi
N=4076
3.6
(1.5 to 8.6)

Tanzania
N=2738
3.9
(1.4 to 9.1)

Uganda
N=6806
5
(1.8 to 9.3)

< 2 year

6513(31.6)

552(29.2)

707(31.8)

954(33.2)

1425(34)

1004(36.7)

1871(27.5)

2-4 years

4170(20.2)

312(16.5)

420(18.9)

471(16.4)

919(23)

495(18.1)

1553(22.8)

5-9 years

5476(26.6)

548(28.9)

614(27.6)

777(27.1)

969(23.8)

674(24.6)

1895(27.8)

10-14 years

4446(21.6)

481(25.4)

483(21.7)

668(23.3)

763(18.7)

565(20.6)

1487(21.9)

10343(50.2)

949(50.2)

1069(48.1)

1438(50.1)

1975(48.5)

1409(51.5)

3503(51.5)

20042

1849

2201

2854

3975

2697

6466

12411(61.9)

1265(68.4)

1445(65.7)

1683(59.0)

2747(69.1)

2033(75.4)

3238(50.1)

18884

1729

2154

2851

3949

2695

5506

11449(60.6)

1231(71.2)

1314(61)

1440(50.5)

2522(63.9)

1928(71.5)

3017(54.8)

17703

1554

2130

2655

2996

2441

5927

3593(20.3)

179(11.5)

481(22.6)

606(22.8)

830(27.7)

513(21.0)

984(16.6)

WAZ, n

20279

1849

2190

2854

4037

2737

6615

median

-2.0

-2.0

-1.7

-2.3

-2.2

-2.4

-1.8

-3.2 to -1.1

-3.0 to -1.1

-2.8 to -0.8

-3.4 to -1.4

-3.4 to -1.2

-3.6 to -1.3

-2.9 to -0.8

5871(29.0)

464(25.1)

483(22.1)

946(33.2)

1380(34.2)

988(36.1)

1610(24.3)

20049

1840

2196

2518

4049

2701

6745

726(3.6)

169(9.2)

12(0.5)

95(3.8)

256(6.3)

130(4.8)

64(1.0)

PITC

7544(37.6)

922(50.1)

83(3.8)

217(8.6)

2928(72.3)

572(21.2)

2822(41.8)

VCT

6904(34.5)

627(34.1)

1982(90.3)

2145(85.2)

404(10.0)

1267(46.9)

479(7.1)

Period
Age, median
(IQR) years
Age group n(%)

Sex
Female (%)
Advanced disease, n
Yes (%)
WHO stage III/IV ,n
Yes (%)
Severe immune
suppression ,n
Yes (%)

IQR
WAZ<-3sd, yes (%)
Care entry
PMTCT

point§,

n

Other
4875(24.3)
122(6.6)
119(5.4)
61(2.4)
461(11.4)
732(27.1)
3380(50.1)
§ PMTCT- prevention of mother to child HIV transmission clinic;IPD-inpatient department;OPD-outpatient department;TB-Tuberculosis unit; VCTvoluntary counseling and testing; others - referrals from other health facilities and outreach.

45

Trends in age at ART initiation
Overall, age at ART initiation fluctuated over time and the change was not significant;
however, it decreased in some countries, remained stable in some, and increased in others. The
median (IQR) age changed from 5.9 (2.9-9.2) years in 2003-05 to 4.2 (1.3-9.9) years in 20162017 but the change was not significant; p=0.9 (Figure 1a, supplementary table 1). The median
age initially decreased between 2003 and 2009, then increased until 2014-15 and declined again
in 2016-17 (Figure 1a). In Uganda, the median age (IQR) declined from 6.7 (3.8-10.6) years in
2003-2005 to 2.1 (0.8-6.2) years in 2016-17; p<0.01 with fluctuations similar to those observed
in the overall median age, while in Tanzania the median age was the same [4.2 (1.5-9.5) years in
2010-2011 to 3.3 (1.4-8.9) years; p=0.1] (Figure 1a, supplementary table 1). In the other
countries the median age increased: Botswana [5.1 (2.2-8.1) years to 9.6 (1.5-12.6) years;
p<0.01]; Eswatini [4.3 (1.6-8.1) years to 8.5 (1.7-11.7) years; p<0.01]; Lesotho [3.9 (1.4-7.9)
years to 8.4 (2.8-11.5) years; p<0.01] and Malawi (5.4 (2.2 to 8.5) years to 6.6 (1.9-10.8) years;
p<0.01) (Figure 1b, supplementary table 1).
Overall, the proportions of children aged <2 years and those aged 10-14 years at ART
initiation increased over time (supplementary table 1); however, similar to the median age, there
were variations across countries. Only Botswana had an increase in both proportions
(supplementary table 1). In Malawi, the proportion of infants decreased, but the proportion of
adolescents increased, while in Uganda the reverse was true (supplementary table 1). Eswatini
and Lesotho had no significant change in the proportion of infants but an increase in the
proportion of adolescents while Tanzania had no significant change in both proportions
(supplementary table 1).
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Figure 1: The median ages at initiation by calendar period. (a) in all countries, Tanzania and
Uganda; (b) in Botswana, Lesotho, Malawi, and Eswatini
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Age-specific trends in advanced disease at ART initiation
Overall, there was a decline in the proportion of children with advanced disease but the
trend varied by age group. The proportion of children with advanced disease declined from
65.3% in 2003-05 to 59.5% in 2016-17; p<0.01 (Fig 2a, supplementary table 2). Initially, the
proportion plateaued between 2003 and 2013, and it declined after that.
By age group, the proportion remained the same in children <2years (72.7% to 70.6%;
p=0.1), increased slightly in children aged 2-4 years (59.4% to 62.3%; p<0.01), but decreased in
children aged 5-9 years (58.3% to 39.9%; p<0.01) and among adolescents aged 10-14 years
(61.9% to 38.1%; p<0.01) (Fig 2b, supplementary table 2). Although the trend was insignificant
among infant, the proportions fluctuated over time. The proportion initially declined from 20032011, then it increased to a peak in 2014-2015, and then declined. The proportion in those 2-4
years increased to a peak in 2012-13 and then declined. The proportion in those aged 5-9 and 1014 plateaued from 2003 to 2013 and declined after that.
Site-specific trends in advanced disease at ART initiation
By country, the proportion of children who initiated ART with advanced disease
decreased in all the countries except Botswana where it remained the same and in Uganda where
it increased. Among countries where the proportion decreased, the magnitude of the decline
varied. The proportion decreased by nearly two-thirds in Malawi (94% to 33%; p<0.01), by half
in Eswatini (69% to 33%; p<0.01) and Lesotho (80% to 34%; p<0.01) (Fig 2c, supplementary
table 1), and by 12% in Tanzania (79% to 69%; p <0.01) (Fig 2d, supplementary table 1). In
Botswana, the proportion remained similar (70% to 52%, p<0.06) while in Uganda, the
proportion increased by 40% (46% to 65%; p<0.01). (Figures 2c-2d, supplementary table 1). At
the end of the analysis period, more than half of the children in Tanzania, Uganda, and Botswana
initiated ART with advanced disease.
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Figure 2: The proportion of children with advanced HIV disease at ART initiation by calendar period. (a) All the six countries
combined (b) By age group (c and d) by country.
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DISCUSSION
This study of 20,605 children with HIV from seven BIPAI COE’s in six countries in ESA
documents trends in age and advanced HIV disease at ART start between 2003 and 2017. We
found that disease severity at ART initiation among children aged 5-14 years has declined,
remained the same in children <2 years and has increased in those aged 2-4 years. Over time,
children initiating ART in most Southern Africa sites are older, and less severely ill, while those
in Eastern Africa sites are younger and more severely ill. In 2016-2017, children initiated ART
within the first week in care but a substantial proportion especially those aged <5yrs still initiated
ART with advanced disease. More efforts are required to diagnose and initiate children on ART
early.
Although the change in age over time was not significant, the fluctuations over time may
reflect changes in WHO guidelines and MTCT rates. The initial decline in median age between
2006 and 2009 is likely due to increased access to early infant diagnosis and WHO
recommendation to initiate ART immediately in all children <2 years13. As a result, more young
children were identified and initiated on ART as is evidenced by the doubling of the proportion
of children <2 years between 2006 and 2009 (Table 3). This initial decline is similar to that
reported in previous studies6, 17, 19, 21. After 2009, we observed an increase up to a peak in 201415. During that period, we observe a decline in the proportion of infants and an increase in the
proportion of adolescents hence increased median age. There are two possible explanations for
this increase. First, from 2010 onwards, new pediatric infections began to decrease in most
countries following the implementation of Option A and Option B+ guidelines for PMTCT1.
Second, the backlog of older children not yet initiated on ART became eligible when the WHO
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guidelines were revised to treat all children aged <5 years and all <15yrs in 2013 and 2015
respectively; thus, the median age increased.
The lack of significance in the overall trend in age is also attributable to variations across
countries. The median age declined in Uganda, remained the same in Tanzania and increased in
the southern Africa sites. The age group of children being initiated likely drives the differences
between the countries. In Uganda, the proportion of children <2 years increased over time while,
the proportion of adolescents decreased. The reverse was true in Eswatini, Lesotho, and Malawi,
whereas in Botswana both proportions increased. The spike in median age observed in Uganda in
2014-2015 coincides with the implementation of the test and start guidelines for all children <15
years27. Uganda started implementing these guidelines in 2014 while the other countries started
in 2016. The increase in age at ART initiation in southern Africa is a concern. Although it is
possible that due to a significant reduction in MTCT rate in these countries, the older children
being diagnosed now are the long-term progressors who missed PMTCT when they were born.
However, there might be a possibility of sexual transmission, especially in young adolescents.
Over 50% of the data on mode of transmission were missing and we cannot ascertain the
possibility of sexual transmission.
Overall, the proportion of children with advanced disease at ART initiation declined over
time. This finding is similar to those previously reported6, 16-18. However, our study found that
the decline observed by examining the proportion in all children (0-14yrs) together masks age
disparities in trends. We found that the proportion with advanced disease at ART initiation
remained the same in children <2 years, increased in children aged 2-4 years and declined in
children aged 5-14 years (Fig 2b). The plausible explanation for the constant proportion of
children <2 years with advanced disease is disease progression in these children is rapid, and by
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the time of diagnosis, most may have progressed to advanced disease. A study on disease
progression in children with HIV showed that by one year of age, 80% of these children have
shown signs of HIV and 55% have progressed to advanced disease28. Additionally, a closer
examination of the trend in children <2 years shows a decline in the proportion of those with
advance disease between 2006 and 2011 (Fig 2b). This decline is likely related to the increased
availability of EID and the WHO recommendation to treat all children under 2-years irrespective
of disease severity13. Similar declines have been reported among infants in southern Africa9, 18.
The increase in the proportion of children <2 years with advanced disease at ART initiation after
2011 occurred likely because over time, more children <2 years were being diagnosed in the
inpatient wards than through PMTCT (table 3). Children identified in inpatient wards are more
likely to have advanced disease than those identified through PMTCT.
Among children aged 2-4 years, the proportion of those with advanced disease increased
slightly. As seen among the children <2 years, this increase is likely because increasingly more
children 2-4 years are being identified through PITC than PMTCT (table 3). Among the children
5-14 years, we observed decline, which happened after 2013 and is likely due to the
implementation of the 2013 and 2015 WHO guidelines. The 2013 WHO guidelines expanded the
CD4 threshold for initiating ART in these children to <500 cells/mm3 and in 2015 recommended
immediate ART upon diagnosis in these children14, 15. Thus, more children who did not have
advanced disease became eligible for ART and were initiated, leading to a decline in the
proportion of children with advanced disease at treatment initiation.
Similar to age-specific trends, we observed differences in country-specific trends of the
proportion of children with advanced disease. There was a decline in the proportion of children
initiating ART with advanced disease in Eswatini, Malawi, Lesotho, and Tanzania, while the
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proportion remained the same in Botswana and increased in Uganda. The differences may be
attributed to the changes in the age of children initiating ART and entry point to care. As we
observed earlier, the proportion of younger children who initiated ART with advanced disease
was higher than that in older children (Fig 2b), and studies show that patients identified through
provider-initiated testing and counseling (PITC) in inpatient wards and outpatients have higher
odds of having advanced disease than those identified through voluntary counseling and testing
VCT)29. The countries where the proportion of children with advanced disease declined were
those where the median age increased and/or enrolled more children through VCT, while in
Uganda where the proportion increased, the median age declined and a significant proportion of
children in later years entered care through PITC (Table 3). The scenarios in Botswana and
Tanzania are different from those in other countries. For example, in Botswana, although the
median age increased over time, the proportion of those with advanced disease remained high
and did not change mainly because most of the children were identified through PITC. In
Tanzania on the other hand, there was a decline in the proportion of children initiating ART with
advanced disease although the median age remained the same. Importantly, the decline in
Tanzania was slight and in 2016/2017, it had the highest number of children initiating treatment
with advanced disease (69.4%).
Despite some of the declines observed, the proportion of children initiating ART with
advanced disease is still a concern. The proportion of children with advanced disease in 20162017 is much higher than observed in central Africa 17 and Europe30. Moreover, we found that in
2016/2017 children initiated ART within five days of entry into care (Fig 1a), meaning most
children who initiated ART with advanced disease had advanced disease at entry into care. Our
findings highlight the need to intensify efforts to diagnose and initiate ART early before children
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develop advanced disease. The benefits of initiating ART with less advanced disease compared
to advanced disease include better survival 2, 6, 8, 30-33 and better growth and development 34-36. In
order to improve early diagnosis of HIV in children, programs should focus not only on testing
children whose mothers are in the PMTCT program but should increase efforts to find those
whose mothers missed PMTCT. The infants whose mothers missed PMTCT can be identified by
providing infant testing in immunization clinics37 and implementing provider-initiated testing in
pediatric inpatient wards and outpatient clinics38-40. Using the point of care early infant diagnosis
testing could improve linkage to treatment and reduce pre-treatment loss to follow-up41, 42.
Our study has multiple strengths: First, it included data for 15 years, which spans over 5periods of WHO guidelines implementation including the most recent “test and start” guidelines.
This has enabled us to how characteristics of children have changed because of WHO guideline
changes. Second, by examining age-specific trends in advanced disease, we are able to show
how guideline changes differentially affected the age groups. Lastly, our study had a large
sample (20,605) of children from six countries in ESA, which enabled us to compare trends
across countries. Nevertheless, our study has several limitations, which should be considered
when interpreting our results. First, there was substantial missing data (30%) for CD4 count and
CD4 percent especially during the implementation of the test and start guidelines for all children
(2015-2017). However, during that period, less than 5% of patients had missing data on the
WHO clinical stage, and hence most patients could be classified as having advanced disease or
not using clinical stage. Second, there is potential for selection bias since these COE’s received
children from referral hospitals, and the patients at referral hospitals are usually very sick
compared to primary care centers. The proportion of children with advanced disease in our study
may not be representative of general trends for that country due to this referral pattern. Third, the
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generalizability of our findings to the countries where these clinics are located may be limited
because the COEs are well resourced and better staffed compared to primary healthcare facilities
in those countries. Notwithstanding, in some countries, these COEs serve a significant proportion
of children with HIV in the country which enhances representativeness, e.g., about 30% of all
children with HIV in Botswana receive care in the COE and about 22% in Lesotho. Lastly,
although changes in WHO guidelines explain some of the changes we observe, our study is
purely descriptive, and it is difficult to attribute causation to guideline changes. Other
interrelated factors like increased health worker training and increased programmatic funding
may have contributed to the changes.

CONCLUSION
Our study shows that between 2003 and 2017, disease severity at ART initiation among
children aged 5-14 years has declined, remained the same in children <2 years and has increased
in those aged 2-4 years. Over time, children initiating ART in most Southern Africa sites are
older, and less severely ill, while those in Eastern Africa sites are younger and more severely ill.
In 2016-2017, children initiated ART within the first week in care but a substantial proportion
especially those aged <5yrs still initiated ART with advanced disease. More efforts are required
to diagnose and initiate children on ART early.
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Supplementary table 1: Characteristics at antiretroviral therapy initiation and entry point to care of children with
HIV overall and by country between 2003-2017 §
Characteristic

Period of ART initiation
2003-05

2006-07

2008-09

2010-11

2012-13

2014-15

2016-17

p for
trend
¥

All Countries
N

1920

3113

3363

3861

3223

3107

2018

<2yrs

45
(15 to 142)
5.9
(2.8 to 9.2)
332(17.3)

55
(28 to 126)
4
(1.6 to 8.4)
999(32.1)

63
(28 to 184)
3.8
(1.4 to 8.5)
1181(35.1)

48
(18 to 259)
4.4
(1.5 to 9.2)
1276(33)

21
(7 to 114)
4.5
(1.4 to 9.7)
1077(33.4)

16
(3 to 356)
5.9
(1.7 to 10.3)
905(29.1)

5
(0 to 22)
4.2
(1.3 to 9.9)
743(36.8)

2-4 yrs

480(25)

732(23.5)

712(21.2)

799(20.7)

602(18.7)

517(16.7)

328(16.3)

5-9 yrs

712(37.1)

857(27.5)

838(24.9)

983(25.5)

789(24.5)

851(27.4)

446(22.1)

10-14yrs

396(20.6)

525(16.9)

632(18.8)

803(20.8)

755(23.4)

834(26.8)

501(24.8)

1832

3025

3282

3750

3174

3051

1928

1132(61.8)

1952(64.5)

2043(62.3)

2440(65.1)

2116(66. 7)

1683(55.2)

1045(54.2)

1866

2821

3308

3780

3198

3074

2002

66(3.5)

127(4.5)

93(2.8)

130(3.4)

119(3.7)

117(3.8)

74(3.7)

PITC

585(31.4)

810(28.7)

1242(37.6)

1510(39.9)

1317(41.2)

1260(41)

820(40.9)

Self-referral/VCT

487(26.1)

1090(38.6)

1361(41.1)

1155(30.6)

1105(34.6)

1020(33.2)

686(34.3)

728(39)

794(28.2)

612(18.5)

985(26.1)

657(20.5)

677(22)

422(21.1)

Time to ART, median
(IQR) days
Age, Median(IQR) years

Advanced disease, n
Yes (%)
Entry point, n
PMTCT

Other

<0.01
0.9
<0.01

<0.01
<0.01

Botswana
N

779

186

271

263

164

124

106

<2yrs

17
(7 to35)
5.1
(2.2 to 8.1)
171(22)

14
(0 to 41)
4.9
(0.8 to 9.9)
73(39.3)

16
(0 to 151)
7.2
(1.5 to 10.9)
78(28.8)

14
(1 to 58)
7.9
(1.0 to 11.2)
87(33.1)

16
(6 to 45)
6.9
(0.8 to 12.1)
66(40.2)

14
(5 to 54)
5.5
(0.8 to 11.8)
46(37.1)

9
(3 to 53)
9.6
(1.5 to 12.6)
31(29.3)

2-4 yrs

211(27.1)

22(11.8)

27(10)

20(7.6)

7(4.3)

14(11.3)

11(10.4)

5-9 yrs

307(39.4)

46(24.7)

74(27.3)

62(23.6)

29(17.7)

17(13.7)

13(12.3)

10-14yrs

90(11.6)

45(24.2)

92(34)

94(35.7)

62(37.8)

47(37.9)

51(48.1)

756

173

264

262

164

124

106

528(69.8)

114(65.9)

174(65.9)

190(72.5)

116(70.7)

88(71)

55(51.9)

754

182

265

256

159

119

105

Time to ART, median
(IQR) days
Age, Median(IQR) years

Advanced disease, n
Yes (%)
Entry point , n
PMTCT

46(6.1)

21(11.5)

35(13.2)

35(13.7)

16(10.1)

8(6.7)

8(7.6)

PITC

266(35.3)

62(34.1)

128(48.3)

167(65.2)

123(77.4)

93(78.2)

83(79)

Self-referral/VCT

406(53.9)

87(47.8)

83(31.3)

24(9.4)

11(6.9)

11(9.2)

5(4.8)

Other

0.6
<0.01
<0.01

<0.01
0.06

36(4.7)
12(6.6)
19(7.2)
30(11.7)
9(5.6)
7(5.9)
9(8.6)
n is the available data for each variable. ¥ The p-values are from Cochrane Armitage test and Cuzick’s test for trends of proportions
and medians respectively over ordered calendar periods of ART initiation.
§
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Supplementary table 1: continued
Characteristic

Period of ART initiation
2003-05

2006-07

2008-09

2010-11

2012-13

2014-15

2016-17

p for
trend
¥

Malawi
N

221

779

892

903

569

405

307

<2yrs

30
(13 to 75)
5.4
(2.2 to 8.5)
49(22.2)

43
(25 to 90)
2.77
(1.4 to 7.4 )
303(38.9)

71
(36 to 166)
2.51
(1.2 to 6.6)
375(42)

66
(21 to 332)
3.79
(1.6 to 8.5)
307(34)

22
(4 to 155)
3.91
(1.4 to 9.4 )
201(35.3)

17
(2 to 362)
5.91
(2.0 to 10.7)
106(26.2)

7
(0 to 175)
6.62
(1.9 to 10.8)
84(27.4)

2-4 yrs

52(23.5)

188(24.1)

219(24.6)

215(23.8)

110(19.3)

84(20.7)

51(16.6)

5-9 yrs

75(33.9)

170(21.8)

181(20.3)

226(25)

134(23.6)

101(24.9)

82(26.7)

10-14yrs

45(20.4)

118(15.2)

117(13.1)

155(17.2)

124(21.8)

114(28.2)

90(29.3)

221

775

875

884

543

388

289

207(93. 7)

649(83.7)

676(77.3)

616(69.7)

327(60.2)

177(45.6)

95(32.9)

221

768

890

894

568

402

306

PMTCT

20(9.1)

93(12.1)

48(5.4)

52(5.8)

21(3.7)

11(2.7)

11(3.6)

PITC

80(36.2)

417(54.3)

727(81.7)

686(76.7)

454(79.9)

312(77.6)

252(82.3)

73(33)

183(23.8)

37(4.1)

43(4.8)

27(4.8)

30(7.5)

11(3.6)

48(21.7)

75(9.8)

78(8.8)

113(12.7)

66(11.6)

49(12.2)

32(10.5)

Time to ART, median
(IQR) days
Age, Median(IQR) years

Advanced disease, n
Yes (%)
Entry point, n

Self-referral/VCT
Other

<0.01
<0.01
0.15

<0.01
<0.01

Uganda
N

920

960

863

1415

920

1085

643

<2yrs

121
(56 to282)
6.7
(3.8 to 10.6)
112(12.2)

93
(42 to 280)
4.9
(2.0 to 9.1)
235(24.5)

92
(43 to 417)
4.5
(1.7 to 8.8)
254(29.4)

51
(24 to 489)
4.2
(1.6 to 8.5)
446(31.5)

15
(6 to 266)
4.7
(1.7 to 9.3)
259(28.1)

14
(2 to 1204)
7.2
(2.2 to 10.4)
254(23.4)

2
(0 to 7)
2.1
(0.8 to 6.2)
311(48.4)

2-4 yrs

217(23.6)

248(25.8)

216(25)

353(25)

215(23.4)

182(16.8)

122(19)

5-9 yrs

330(35.8)

279(29.1)

226(26.2)

354(25)

238(25.9)

341(31.4)

127(19.7)

10-14yrs

261(28.4)

198(20.6)

167(19.4)

262(18.5)

208(22.6)

308(28.4)

83(12.9)

855

898

811

1335

912

1061

594

397(46.4)

309(34.4)

339(41.8)

782(58.6)

554(60.8)

466(43.9)

391(65.8)

Entry point, n

891

949

856

1406

918

1082

643

PMTCT

0(0)

6(0.6)

0(0)

18(1.3)

17(1.9)

17(1.6)

6(0.9)

239(26.8)

272(28.7)

362(42.3)

558(39.7)

503(54.8)

582(53.8)

306(47.6)

8(0.9)

5(0.5)

7(0.8)

129(9.2)

95(10.3)

115(10.6)

120(18.7)

Time to ART, median
(IQR) days
Age, Median(IQR) years

Advanced disease, n
Yes (%)

PITC
Self-referral/VCT
Other

644(72.3)
666(70.2)
487(56.9)
701(49.8)
303(33)
368(34)
211(32.8)
n is the available sample size for each variable. ¥ The p-values are from Cochrane Armitage test for categorical variables and
Cuzick’s test for continuous variables over ordered calendar periods of ART initiation.
§
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<0.01
<0.01
<0.01

<0.01
<0.01

Supplementary table 1: continued
Characteristic

Period of ART initiation
2006-07

2008-09

2010-11

2012-13

2014-15

2016-17

p for
trend ¥

Eswatini
N

565

612

468

206

205

166

Time to ART, median
(IQR) days
Age, Median
(IQR) years
<2yrs

56
(32 to 113)
4.29
(1.6 to 8.1)
172(30.4)

56
(28 to 143)
4.67
(1.5 to 8.8)
201(32.8)

46
(19 to 229)
4.25
(1.3 to 8.9)
170(36.3)

55
(21 to 269)
4.74
(1.5 to 10.5)
69(33.5)

42
(16 to 572)
7.24
(2.0 to 10.8)
51(24.9)

28
(9 to 1367)
8.54
(1.7 to 11.7)
44(26.5)

2-4 yrs

136(24.1)

115(18.8)

80(17.1)

39(18.9)

34(16.6)

16(9.6)

5-9 yrs

177(31.3)

173(28.3)

126(26.9)

39(18.9)

58(28.3)

40(24.1)

10-14yrs

80(14.2)

123(20.1)

92(19.7)

59(28.6)

62(30.2)

66(39.8)

557

610

463

202

204

165

385(69.12)

446(73.11)

342(73.87)

121(59.9)

97(47.55)

54(32.73)

550

609

464

204

203

166

PMTCT

6(1.1)

3(0.5)

3(0.6)

0(0)

0(0)

0(0)

PITC

37(6.7)

5(0.8)

4(0.9)

1(0.5)

9(4.4)

27(16.3)

480(87.3)

579(95.1)

430(92.7)

193(94.6)

180(88.7)

120(72.3)

27(4.9)

22(3.6)

27(5.8)

10(4.9)

14(6.9)

19(11.4)

Advanced disease, n
Yes (%)
Entry point, n

Self-referral/VCT
Referrals from other health
facilities/outreach

0.2
<0.01
0.5

<0.01
<0.01

Lesotho
N

623

725

519

396

361

246

<2yrs

36
(22 to 79)
3.9
(1.4 to 7.9)
216(34.7)

42
(21 to 126)
3.8
(1.0 to 8.2)
273(37.7)

56
(23 to 333)
6.0
(1.3 to 10.2)
171(33)

43
(20 to 189)
6.2
(1.6 to 10.1)
134(33.8)

29
(14 to 272)
6.7
(1.5 to 10.9)
114(31.6)

24
(2 to 764)
8.4
(2.8 to 11.5)
46(18.7)

2-4 yrs

138(22.2)

135(18.6)

67(12.9)

46(11.6)

50(13.9)

35(14.2)

5-9 yrs

185(29.7)

184(25.4)

147(28.3)

112(28.3)

82(22.7)

67(27.2)

10-14yrs

84(13.5)

133(18.3)

134(25.8)

104(26.3)

115(31.9)

98(39.8)

622

722

513

391

361

245

495(79.6)

408(56.5)

301(58.7)

230(58.8)

166(46.0)

83(33.9)

372

688

477

389

349

243

PMTCT

1(0.3)

7(1)

2(0.4)

26(6.7)

42(12)

17(7)

PITC

22(5.9)

20(2.9)

33(6.9)

36(9.3)

55(15.8)

51(21)

335(90.1)

655(95.2)

441(92.5)

326(83.8)

240(68.8)

148(60.9)

Time to ART, median
(IQR) days
Age, Median(IQR) years

Advanced disease, n
Yes (%)
Entry point, n

Self-referral/VCT
Other

0.08
<0.01
0.004

<0.01
<0.01

14(3.7)
6(0.9)
1(0.2)
1(0.3)
12(3.4)
27(11.1)
n is the available data for each variable. ¥ The p-values are from Cochrane Armitage test and Cuzick’s test for trends of proportions
and medians respectively over ordered calendar periods of ART initiation.
§
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Supplementary table 1: continued
n is the available data for each variable. ¥ The p-values are from Cochrane Armitage test and Cuzick’s test for trends of proportions
and medians respectively over ordered calendar periods of ART initiation.
p for
Period of ART initiation
¥
trend
Characteristic
§

2006-07

2008-09

2010-11

2012-13

2014-15

2016-17

293

968

927

550

<2yrs

20
(10 to 45)
4.2
(1.5 to 9.5)
95(32.4)

17
(6 to 53)
4
(1.4 to 8.9)
348(36)

12
(2 to 41)
4.4
(1.5 to 9.1)
334(36)

3
(0 to 14)
3.3
(1.3 to 8.9)
227(41.3)

2-4 yrs

64(21.9)

185(19.1)

153(16.5)

93(16.9)

5-9 yrs

68(23.2)

237(24.5)

252(27.2)

117(21.3)

10-14yrs

66(22.5)

198(20.4)

188(20.3)

113(20.5)

293

962

913

529

209(71.33)

768(79.83)

689(75.47)

367(69.38)

283

960

919

539

PMTCT

20(7.1)

39(4.1)

39(4.2)

32(6.0)

PITC

62(21.9)

200(20.8)

209(22.8)

101(18.7)

Self-referral/VCT

88(31.1)

453(47.2)

444(48.3)

282(52.3)

Other

113(39.9)

268(27.9)

227(24.7)

124(23.0)

Tanzania
N
Time to ART, median
(IQR) days
Age, Median(IQR) years

Advanced disease, n
Yes (%)
Entry point, n

59

<0.01
0.1
0.2

<0.01

Supplementary table 2: Age-specific trends in advanced HIV disease at antiretroviral therapy
initiation among children with HIV in all countries: 2003-2017 §
Calendar period of ART initiation
Characteristic

< 2 year, n
Yes (%)
2-4 years, n
Yes (%)
5-9 years, n
Yes (%)
10-14 years, n

2003-05
N=1920

2006-07
N=3113

2008-09
N=3363

2010-11
N=3861

2012-13
N=3223

2014-15
N=3107

2016-17
N=2018

318

983

1163

1243

1052

868

698

231(72.7)

718(73)

805(69.2)

854(68.7)

764(72.6)

668(77)

493(70.6)

458

713

692

775

597

511

313

272(59.4)

431(60.5)

415(60)

488(63)

409(68.5)

336(65.8)

195(62.3)

682

819

815

952

780

844

426

397(58.2)

506(61.8)

459(56.3)

624(65.6)

505(64.7)

386(45.7)

170(39.9)

374

510

612

780

745

828

491

Yes (%)
232(62.0)
297(58.2)
364(59.5)
474(60.8)
438(58.8)
293(35.4)
187(38.1)
§
¥
n is the available data for each variable. The p-values are from Cochrane Armitage test for trends of proportions
over ordered calendar periods of ART initiation.
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p for
trend¥

0.1
<0.01
<0.01
<0.01
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ABSTRACT
Introduction
Despite providing pediatric antiretroviral therapy (ART) for >10 years, data on long-term survival of
HIV-infected children receiving ART in resource-limited settings are scarce. We describe 10-year
survival and risk factors for early mortality in HIV-infected children receiving ART.
Methods
We conducted a retrospective cohort study of HIV-infected children (0-14 years) who initiated ART
between 2006-2017 at seven centers of excellence in Botswana, Eswatini, Lesotho, Malawi,
Tanzania, and Uganda. Time to death was measured from the ART initiation date, and children were
right-censored at the earliest of either LTFU, transfer out, 10-years of follow-up or database closure
date (Dec 31, 2019). We estimated the 10-year survival probability using Kaplan-Meier methods and
assessed risk factors for mortality using Cox proportional hazard regression
Results
Among 18,010 children (median age, 4.5 years; girls, 50%; half were girls), 1528 (8.5%) died, 3333
(18.5%) transferred, 1633 (9.1%) were LTFU, and 11,516 (63.9%) remained in care. Half of the
deaths were within 6-months of therapy (mortality rate=9.17, 95% CI: 8.55-9.84 per 100 PY). 10year survival probability %( 95%CI) was 88.9 (88.3-89.5) overall, 83.7 (82.5-84.8) in children aged
<2 years, 91.9 (90.7-93.0) in those 2-4 years, 92.6 (91.5-93.6) in 5-9 years and 88.8 (9 87.2-90.2) in
10-14 years. The 10-year survival probability in Botswana was 91.7(89.1-93.7), 89.8(88.1-91.2) in
Eswatini, 86.9(85.2-88.4) in Lesotho, 86.5(84.9-88.0) in Malawi and 90.7(89.6-91.6) in Uganda. In
Tanzania, the 5-year survival probability was 89.5(88.0-90.9). The risk factors of mortality were:
baseline age <2 years (aHR 1.41(95% CI: 1.11-1.79) compared to 10-14 years; WHO stage 4 (aHR
2.95(95% CI 2.33-2.72) and stage 3 (aHR 1.36(95% CI: 1.06-1.73) compared to stage 1 and 2
disease; severe (aHR=6.71, 95% CI 5.29-8.52) and moderate (aHR=2.64, 95% CI 1.90-3.66)
67

immune suppression compared to no/mild immune suppression; and severe underweight (aHR 1.84
(95% CI 1.48-2.29) compared to normal weight-for-age.

Conclusion
10-year survival in children receiving ART is good. Mortality is highest in the first 6-months of ART
and young age (<2 years), advanced HIV disease and severe underweight at ART initiation were
associated with a higher risk of early mortality. Our findings re-emphasize the need for early infant
diagnosis and treatment and close monitoring during the first 6-months of therapy as measures to
reduce mortality of HIV-infected children receiving ART.
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INTRODUCTION
For nearly one and a half decades, combination antiretroviral therapy (ART) has been the
standard approach for treating pediatric HIV in the Eastern and Southern Africa region (ESA). Since
its introduction in the region, ART has improved short-term survival of HIV-infected children 1-4.
Additionally, several programmatic improvements that could further improve the survival of children
have been implemented. For example, the 2015 WHO recommendation to initiate ART in all children
upon diagnosis irrespective of disease severity have been implemented by countries, and more
effective pediatric antiretrovirals (ARV’s) have become available over time5.
Despite the improved survival and programmatic improvements, in resource-limited settings,
long-term pediatric ART care presents challenges that could affect the success of ART and long-term
survival. For example, lack of appropriate pediatric ARV formulations, ARV stock outs, and health
care workers need to adjust treatment doses as the child’s weight increases; yet, children may not
adhere to clinic appointments 6, 7. Moreover, children are vulnerable because they depend on
caregivers, who may be too sick to administer their medicines and as they grow into adolescents, they
may not adhere to treatment 8, 9. All these challenges could lead to poor long-term adherence to ART,
which can result in treatment failure, disease progression, and death.
Even with over 10-years’ experience providing pediatric ART, data on long-term survival of
children initiating ART are mainly from high and middle-income countries, and those from RLS are
scarce; yet, challenges of providing pediatric ART in these settings may differ. Studies from high and
middle-income countries report 5-10 year mortality rates of 1.2-1.7 deaths per 100 person-years and a
survival probability of >94-99% 10-14. One study from Mozambique that examined survival in
children receiving ART reported 8-years survival probability of 90% 15. Limited data on long-term
survival of children receiving ART in RLS precludes our understanding of the impact of ART
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programs on long-term survival in HIV infected children, and yet significant investments have been
made to improve survival in children with HIV.
The Baylor International Pediatric AIDS Initiative (BIPAI) includes a network of seven
clinical centers of excellence (COE) in six countries in Eastern and Southern Africa that have
provided pediatric ART for over ten years 16. Data from the BIPAI network, therefore, provides an
opportunity to examine long-term survival of children receiving ART. Our study examined agespecific survival at ten years of ART and risk factors for early mortality in HIV infected children who
initiated ART between 2003-2017 in the BIPAI network clinics.

METHODS
Study design, setting, and population
This study was a retrospective cohort study using patient-level data pooled from seven BIPAI
COEs in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda. These COEs are operated in
partnership with the respective governments and receive substantial funding for distribution of ART
from the Presidential Emergency Plan for AIDS Relief (PEPFAR). They provide free comprehensive
HIV/AIDS prevention and treatment services to children and adolescents with HIV. Children at all
the COEs receive clinical care at least 3-monthly. Shorter clinic appointments are given at the start of
therapy and when medically required. The data at the sites are managed using a standardized
electronic medical record system (EMR).
We included children with HIV aged <15 years who initiated ART between January 2006 and
June 2017 and had two or more follow-up visits after ART initiation. Children who were ARV
experienced (except for exposure to ARVs for PMTCT) at entry into care were excluded. The cohort
start date for Tanzania was 2010, corresponding to the period when the clinic became operational.
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The individual patient data were pooled electronically, anonymized and transferred to the
research team for cleaning and management. Ethical approvals (with a waiver of informed consent)
were obtained from the individual country institutional review boards (IRB), Baylor College of
Medicine IRB and University of Texas Health Science Center at Houston Committee for the protection
of human subjects.
Study variables and definitions
The independent study variables were age, sex, country, weight, height, WHO clinical stage,
CD4 count, CD4 percent, weight for age Z-scores (WAZ), BMI for age Z scores (BAZ), ART
regimens, TB diagnosis, hemoglobin levels(Hb) and immune suppression level. The child’s weight or
height was considered to be at ART start if they were taken ± 1month from the ART start date, while
WHO stage and CD4 count or percent at ART start were taken on or at a date closest to the ART
initiation date within six months before and one month after ART initiation. We computed the WAZ
for children aged < 10 years and BAZ for all children using the WHO child growth standards 17, 18.
WAZ for children aged 10-14 years using the Centers for Diseases Control and Prevention (CDC)
growth standards 19 because this measure was not available for the age group in the WHO growth
standards. CD4 counts or CD4 percentage were categorized into immune suppression levels (no/mild,
moderate or severe) for age according to the WHO classification 20, 21. The calendar period of ART
initiation was categorized into three, 4-year periods: 2006-2009, 2010-2013 and 2014-2017
corresponding to WHO guideline periods; 2014-2017 covered two guideline periods.
The main outcome variable was all-cause mortality and was defined as death from any cause
including HIV related and non-HIV related deaths. The date of death was extracted from the EMR. If
the date was missing, we used the date the chart was closed. Other events that were censored in the
analysis were lost to follow-up (LTFU), transfer out and active in care. The patient was considered
LTFU if there was a gap of 90 days between their next clinic appointment and the database closure
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date (December 31, 2017). The date of LTFU was the chart closure date, and if the chart was not
closed, the patient was censored 90 days after the last scheduled appointment. The patient was
considered transferred-out if the transfer was documented and the date of transfer was that recorded
in the chart.
Statistical analysis
Patient characteristics at ART initiation were described using summary statistics (medians and
proportions) by age groups (<2 years, 2-4 years, 5-9 years and 10-14 years). We computed overall
mortality rates per 100 person-years(PY) and rates within the first six months of ART, at 6-24 months
and after 24 months. Kaplan-Meier estimates for 10-year survival probability was calculated overall,
by age group, country, and calendar period of ART initiation; differences in survival curves were
tested using the log-rank test. Time to death was computed from the date of ART initiation, and
children were right-censored at the earliest of either LTFU, transfer out, 10-years of follow-up or
database closure date. We examined risk factors of mortality in the first 6-months and 6-24 months
on ART using univariable and multivariable Cox proportional hazard regression models. We limited
the analysis to the first 24 months to enable us to examine the effect of the most recent WHOtreatment guidelines (2014-2017) on survival. We used a stepwise regression method to select the
most parsimonious model. The criteria for a variable to enter and to stay in the model were p≤0.15
and p≤0.05, respectively. Known predictors of death, including WHO clinical stage, immune
suppression level, and age were purposefully included in the analysis. We tested the proportional
hazards assumption using the Schoenfield test. To avoid loss of information and biased estimates
because of missing data, we imputed missing CD4, WHO stage, WAZ, and Hb values using multiple
imputation by chained equations (MICE), using 20 cycles22, 23. We conducted sensitivity analyses
using complete case analysis and competing risks analyses with LTFU as the competing risk.
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RESULTS
Characteristics of participants
Overall, 23,510 children with HIV initiated ART between January 2006 and June 2017 at the
BIPAI COEs, of whom 22,995 were <15 years of age. Of these, 4721 were excluded because they
were not ART naïve at the time of enrollment in care at the study sites. These children transferred
care to the study sites while they were already receiving ART and we did not have their baseline
characteristics at ART initiation. In addition, we excluded 264 children who had only one medical
visit after initiating ART, leaving 18,010 who were included in the study (Figure 1).
Table 1 describes patients’ characteristics at ART initiation by age group. Of the 18,010
children included in the study, half were girls and the median age was 4.5 [interquartile range (IQR):
1.5-9.4] years. A third of all children were from Uganda and most initiated ART during 2010-2013.
Most of the children (32.6%) were aged <2 years, 19.8% were 2-4 years, 25.7% 5-9 years and 21.9%
were 10-14 years; 24.2% of all children had stage 4 disease, 17.8% had severe immune suppression,
and 28.4% were severely underweight. Stage 4 disease, severe immune suppression and underweight
were more frequent in the children <2 years than the other age groups (Table 1). Among all children,
86% initiated ART with nucleoside reverse transcriptase inhibitor (NNRTI) based regimens, but the
frequency varied from 70% among infants to 95% among those aged 5-9 years.
The median duration of follow-up was 4.34 (IQR: 1.69-7.47) years with 85,140 person-years
(PY) of follow-up overall. Of the overall person-time, 25,076 PY were of children aged <2 years,
18,008 PY aged 2-4 years, 23,522 PY aged 5-9 years and 18,534 aged 10-14 years. During follow-up,
1528 (8.5%) children died, 3333 (18.5%) transferred care to other health facilities, 1633 (9.1%) were
LTFU, and 11,516 (63.9%) were still in care by the end of the study. Half of the deaths occurred
within six months of ART and 78% within 2-years of ART.
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Figure 1: Flow chart
Initiated ART between 2006 and June 2017
N=23,510
Age at ART start ≥15years, n=515
ART-naive at enrollment
n=22,995
Not ART-naive at enrolment, n=4,721
ART-naive <15 yrs
n=18,274
Only one medical visit, n=264
ART naive <15 yrs
n=18,010

Mortality rates
The mortality rate among all children was 1.79 deaths per 100 PY. Mortality during the first 6
months of receiving ART was 9.17 (95% CI: 8.55-9.84) deaths per 100 PY. The rate declined to 1.95
(95% CI: 1.77-2.14) deaths per 100 PY between 6-month to 2 years and thereafter it reduced to 0.59
(95% CI: 0.53-0.65) deaths per 100 PY. Mortality rates per 100 PY were 17.5 (95% CI: 16-19.2) in
children <2 years, 6.8 (95% CI: 5.6-8.1) in 2-4 years, 4.7 (95% CI: 3.9-5.7) in 4-9 years and 4.8 (95%
CI: 3.9-5.9) in the 10-14 year old. The combined probability of surviving up to 10-years on ART was
88.9% (95% CI: 88.3%-89.5%). Children <2 years of age had the lowest 10-year survival probability
[83.7% (95% CI: 82.5%-84.8%)] as compared to 91.9% (95% CI: 90.7%-93.0%) in those 2-4 years,
92.6 % (95% CI: 91.5%-93.6%) in 5-9 years and 88.8% (95% CI: 87.2%-90.2%) (Figure 2).
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Table 1. Patient characteristics at ART start stratified by age.
Characteristic

Total
(N=18010)

<2 years
(N=5869)

2-4 years
(N=3570)

5-9 years
(N=4631)

10-14 years
(N=3940)

Age, median(IQR) years

4.5(1.5-9.4)

1(0.6-1.5)

3.2(2.5-4.1)

7.6(6.3-8.8)

12.2(11.1-13.4)

Female

9046(50.2)

2916(49.7)

1711(47.9)

2313(50)

2106(53.5)

Male

8964(49.8)

2953(50.3)

1859(52.1)

2318(50.1)

1834(46.6)

1&2

6783(37.7)

1810(30.8)

1288(36.1)

1792(38.7)

1893(48.1)

3

5607(31.1)

1650(28.1)

1186(33.2)

1673(36.1)

1098(27.9)

4

4363(24.2)

2036(34.7)

812(22.8)

812(17.5)

703(17.8)

1257(7)

373(6.4)

284(8)

354(7.7)

246(6.2)

11.4(10-12.4)

10.6(9.2-11.8)

11.3(9.9-12.3)

11.7(10.7-12.7)

12.2(11.1-13.1)

None/mild

10490(58.3)

2791(47.6)

2171(60.8)

3182(68.7)

2346(59.5)

moderate

1891(10.5)

592(10.1)

286(8)

478(10.3)

535(13.6)

Severe

3206(17.8)

1567(26.7)

654(18.3)

429(9.3)

556(14.1)

missing

2423(13.5)

919(15.7)

459(12.9)

542(11.7)

503(12.8)

None/mild/mod

12662(70.3)

3287(56)

2741(76.8)

3744(80.9)

2890(73.4)

Severe

5120(28.4)

2546(43.4)

775(21.7)

797(17.2)

1002(25.4)

missing

228(1.3)

36(0.6)

54(1.5)

90(1.9)

48(1.2)

NNRTI based

15481(86)

4123(70.3)

3168(88.7)

4430(95.7)

3760(95.4)

PI- based/other

2529(14)

1746(29.7)

402(11.3)

201(4.3)

180(4.6)

2006-2009

6417(35.6)

2154(36.7)

1431(40.1)

1683(36.3)

1149(29.2)

2010-2013

7010(38.9)

2306(39.3)

1392(39)

1760(38)

1552(39.4)

2014-2017

4583(25.5)

1409(24)

747(20.9)

1188(25.7)

1239(31.4)

Botswana

1062(5.9)

363(6.2)

94(2.6)

230(5)

375(9.5)

Eswatini

2153(12)

681(11.6)

411(11.5)

597(12.9)

464(11.8)

Lesotho

2831(15.7)

938(16)

465(13.1)

771(16.6)

657(16.7)

Malawi

3750(20.8)

1321(22.5)

843(23.6)

880(19)

706(17.9)

Tanzania

2557(14.2)

923(15.7)

460(12.9)

634(13.7)

540(13.7)

Uganda

5657(31.4)

1643(28)

1297(36.3)

1519(32.8)

1198(30.4)

Sex, n (%)

WHO clinical stage, n (%)

missing
Hemoglobin(mg/dl)
Immune Suppression, n (%)

Underweight, n (%)

ART regimen, n (%)

Period of ART start, n (%)

Country, n (%)

Outcomes, n (%)
Active in care

11516(63.9)

3230(55)

2253(63.1)

3248(70.1)

2785(70.7)

Died

1528(8.5)

799(13.6)

224(6.3)

230(5.0)

275(7.0)

Lost to follow-up

1633(9.1)

743(12.7)

362(10.1)

265(5.7)

263(6.7)

Transferred out

3333(18.5)

1097(18.7)

731(20.5)

888(19.2)

617(15.6)
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Figure 2: Survival probability after initiating ART by age at initiation among 18,010 children
with HIV in BIPAI COEs in six African countries, 2003-2017.

Long-term survival by country and period of ART initiation
Fig 3a and 3b show survival probabilities after initiating ART by country and by year of ART
initiation respectively. Overall, there were significant country differences in 10-year survival
(Log-rank p<0.01). The 10-year survival probabilities were similar in Botswana, Uganda, and
Eswatini, and the survival probabilities in these countries were higher than those in Malawi and
Lesotho. Children in Tanzania had not accrued up to 10 years of follow-up; however, at 5-years
of follow-up, they had lower survival probability than those in Botswana and Uganda
(supplementary table 1). The survival probabilities did not differ by year of ART initiation (Fig
3b and Supplementary Table 1).
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Figure 3: Survival probability after initiating ART by COE and period of initiation among
18,010 children with HIV in BIPAI COE’s in six African countries, 2003-2017. By COE (a) and
period of ART initiation (b)
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Factors associated with mortality within six months of ART
In multivariable regression analysis of short-term mortality, the factors associated with a
higher risk of death were: being <2 years of age compared to age 10-14 years, stage 3 and stage 4
disease compared to stage 1 or 2, moderate or severe immune suppression compared to no or
mild immune suppression, underweight compared to normal weight for age (Table 2).
Additionally, compared to Uganda, children who initiated ART in Lesotho had a higher risk of
death, while those who initiated in Botswana, Malawi, and Tanzania had a lower risk of death.
Children who initiated ART between 2014-2017 had a lower risk of death than those who
initiated ART between 2006-2009, and an increase in hemoglobin levels was associated with a
lower risk of death. There was no difference in risk between the ART regimens. Sensitivity
analysis with complete case analysis and competing risks analysis found similar associations
(supplementary table 2)
Factors associated with mortality after between 6-24 month of receiving ART
After six months on ART, age <2 years, time updated stage 3&4 disease stage, moderate
or severe immune suppression and underweight continued to be associated with a higher risk of
disease. Variables that were not significantly associated with death in the first six months of
ART but became significant after six months are baseline age 5-9 years compared to age 10-14
years, PI-based regimen compared to NNRTI-based regimen and initiating ART in 2010-2013
compared to initiating in 2006-2009 (Table 2). Except Malawi where the risk of death remained
lower, there was no longer a difference in risk between other sites and Uganda.
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Table 2: Risk factors for deaths within the first six months of ART and during 6-24months of ART.
Characteristic

No of
deaths

Mortality
rate/ 100
PY

0-6 months, N=18,010
Univariableβ
HRδ

95%CI

Adjusted
HRδ

95% CI

No of
deaths

6-24 months., N=16,289†
Mortality
Univariableβ
Adjusted
rate/ 100
HRδ
95%CI
HRδ
95% CI
PY

Age(years)
10-14
91
4.76
1
1
88
1.77
1
1
5-9
106
4.75
1.00
0.75, 1.32
1.13
0.85, 1.50
54
0.92
0.52
0.37, 0.73
0.71
0.50, 1.00
2-4
115
6.76
1.41
1.07, 1.86
1.00
0.76, 1.33
48
1.09
0.62
0.43, 0.88
0.78
0.54, 1.13
<2
471
17.5
3.62
2.9, 4.54
1.41
1.11, 1.79
233
3.63
2.04
1.6, 2.61
1.63
1.25, 2.13
WHO clinical stage
1&2
109
3.30
1
1
96
1.12
1
1
3
180
6.71
2.02
1.59, 2.56
1.36
1.06, 1.73
133
1.90
2.4
1.84, 3.13
1.64
1.25, 2.15
4
464
23.87
7.08
5.75, 8.72
2.95
2.33, 3.73
171
3.78
6.05
4.7, 7.78
2.52
1.91, 3.32
Immune suppression level
None/mild
102
1.97
1
1
0.73
1
1
Moderate
63
7.01
3.52
2.57, 4.81
2.64
1.90, 3.66
104
2.07
5.16
3.51, 7.6
2.75
1.9, 3.99
Severe
426
30.83
15.09 12.16, 18.73
6.71
5.29, 8.52
46
6.97
10.24 7.43, 14.11
4.05
2.86, 5.72
Hemoglobin mg/dl
0.65
0.63, 0.67
0.75
0.72, 0.78
201
0.69
0.66, 0.73
0.75
0.71, 0.79
Underweight
None/mild
141
3.34
1
1
98
0.88
1
1
Moderate
142
7.45
2.22
1.75, 2.8
1.25
0.98, 1.59
78
1.59
2.05
1.53, 2.76
1.94
1.46, 2.59
Severe
491
21.31
6.25
5.18, 7.54
1.84
1.48, 2.29
244
4.52
6.85
5.32, 8.84
4.23
3.25, 5.52
Regimen
NNRTI_based
618
8.40
1
1
362
1.90
1
1
PI_based
165
14.01
1.66
1.4, 1.97
0.86
0.71, 1.06
61
2.27
1.17
0.89, 1.54
0.67
0.49, 0.91
Period of ART start
2006-2009
276
9.06
1
1
187
2.30
1
1
2010-2013
324
9.77
1.08
0.92, 1.26
1.17
0.98, 1.39
154
1.76
0.76
0.62, 0.94
0.75
0.59, 0.96
2014-2017
183
8.42
0.93
0.77, 1.12
0.77
0.62, 0.96
82
1.69
0.71
0.55, 0.92
0.67
0.49, 0.91
Country‡
Uganda
239
8.83
1
1
100
1.39
1
1
Botswana
27
5.24
0.59
0.4, 0.88
0.62
0.41, 0.94
16
1.15
0.83
0.49, 1.4
0.62
0.36, 1.07
Eswatini
98
8.41
0.94
0.75, 1.19
1.05
0.82, 1.35
49
2.39
1.38
0.98, 1.95
0.94
0.65, 1.34
Lesotho
148
9.64
1.08
0.86, 1.37
1.28
1.03, 1.59
85
1.94
1.78
1.33, 2.37
1.21
0.89, 1.63
Malawi
170
11.04
1.25
1.01, 1.53
0.72
0.58, 0.90
104
2.49
1.72
1.31, 2.26
0.61
0.45, 0.82
Tanzania
101
9.69
1.09
0.89, 1.32
0.63
0.49, 0.80
69
2.41
1.7
1.25, 2.31
1.02
0.73, 1.43
¥
PY- person-years; δHR- Hazard ratio; Bold figure show adjusted HR with p<0.05; β TB and sex were significant at univariable analysis and not at multivariable
analysis. † Disease stage, immune suppression, underweight and hemoglobin measures were time-updated. ‡ Uganda was selected as a reference because it had
the largest frequency.
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Supplementary table 1: Kaplan-Meier estimates of survival probabilities % (95% CI) of
children with HIV receiving antiretroviral therapy by age group, site and period of ART
initiation.
Time to death from ART initiation
Characteristic

6 months

2 years

5 years

10 years

<2 years

91.8(91.1-92.5)

87.1(86.2-88.0)

85.2(84.2-86.1)

83.7(82.5-84.8)

2-4 years

96.7(96.1-97.3)

95.2(94.4-95.8)

93.5(92.5-94.3)

91.6(90.3-92.8)

4-9 years

97.7(97.2-98.1)

96.4(95.8-96.9)

95.1(94.4-95.7)

92.7(91.5-93.8)

10-14 years

97.7(97.1-98.1)

95.1(94.4-95.8)

92.9(92.0-93.7)

88.6(86.7-90.2)

Botswana

97.4(96.3-98.2)

95.8(94.4-96.9)

93.8(92.1-95.2)

91.7(89.1-93.7)

Eswatini

95.4(94.4-96.2)

92.7(91.5-93.8)

91.3(89.9-92.5)

89.8(88.1-91.2)

Lesotho

94.7(93.8-95.5)

91.3(90.2-92.3)

89.6(88.3-90.7)

86.9(85.2-88.4)

Malawi

95.3(94.6-96.0)

92.0(91.1-92.9)

89.8(88.7-90.8)

86.5(84.9-88.0)

Tanzania

96.0(95.1-96.7)

92.7(91.5-93.7)

89.5(88.0-90.9)

Uganda

95.7(95.2-96.2)

93.8(93.1-94.4)

92.6(91.9-93.3)

90.7(89.6-91.6)

2006-2009

95.6(95.1-96.1)

92.4(91.7-93.1)

90.5(89.7-91.2)

88.2(87.3-89.1)

2010-2013

95.3(94.8-95.8)

92.9(92.2-93.5)

91.3(90.5-91.9)

2014-2017

95.9(95.3-96.5)

93.7(92.9-94.4)

Age group

Country

Period of ART initiation
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Supplementary table 2: Risk factors for death after complete care analysis and competing risk
analysis.
Complete case analysis
0-6 months
N=12332

Characteristic

aHRδ

Competing risk analysis‡

6-24 month
N=7246

95% CI

aHRδ

1
1.28
0.79

0.91, 1.79
0.55, 1.14

1.42

1.06, 1.89

1
0.80
1.09
1.27

1
1.44
3.18

1.07, 1.95
2.38, 4.24

1
1.34
2.78

0-6 months
N=18010

95% CI

asHR¥

95% CI

0.43, 1.51
0.59, 2.00
0.77, 2.09

1
1.13
1.00
1.4

0.85, 1.50
0.76, 1.32
1.1, 1.78

0.82, 2.18
1.75, 4.41

1
1.36
2.94

1.06, 1.73
2.29, 3.77

1.91, 5.45
3.18, 7.60
0.71, 0.83

1
2.62
6.62
0.75

1.88, 3.65
5.16, 8.51
0.72, 0.78

0.70, 1.91
2.01, 4.86

1
1.25
1.83

0.97, 1.61
1.45, 2.32

Age(years)
10-14
5-9
2-4
<2
WHO clinical stage
1&2
3
4
Severe immune suppression
None/mild
Moderate
Severe
Haemoglobin mg/dl
Underweight
None/mild
Moderate
Severe
Regimen
NNRTI_based
PI_based
Period of ART start
2006-2009
2010-2013
2014-2017
Country
Uganda
Botswana
Eswatini
Lesotho
Malawi
Tanzania

1
2.39
6.82

1.69, 3.39
5.34, 8.7

0.73

0.7, 0.76

1
3.23
4.92
0.76

1
1.1

0.82, 1.47

1.58

1.22, 2.04

1
1.15
3.13

0.62, 1.04

1
0.69

0.34, 1.37

1
0.87

0.7, 1.08

0.95, 1.45
0.57, 1.05

0.55
0.40

0.34, 0.89
0.19, 0.83

1
1.17
0.78

0.99, 1.39
0.63, 0.97

0.08, 1.49
0.31, 1.24
0.44, 1.52
0.44, 1.54
0.47, 1.66

1
0.64
1.07
1.31
0.73
0.62

0.42, 0.97
0.83, 1.36
1.05, 1.62
0.58, 0.92
0.49, 0.80

1
0.8
1
1.17
0.77
1
0.74
1.09
1.36
0.78
0.42

0.34
0.62
0.82
0.82
0.89

0.42, 1.32
0.81, 1.46
1.05, 1.76
0.57, 1.05
0.3, 0.58

δ

aHR-adjusted hazard ratio; ¥sHR- sub distributional hazard ratio; ‡ Loss to follow-up was considered a
competing risk.
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DISCUSSION
In this study, we report age-specific 10-year survival and factors associated with early
mortality in a cohort of 18,010 children with HIV, who initiated ART between 2006 and 2017 in
BIPAI clinics in six countries in Eastern and Southern Africa. We report three findings. First, the
10-year survival probability of children living with HIV on ART was good (88.9%); however,
children aged <2 years at baseline had poorer survival than older children, and this persisted
beyond the first six months on ART. Second, mortality was highest in the first six months but
declined after that. Lastly, advanced disease stage, severe immune suppression and underweight
were associated with increased risk of early mortality, but mortality risk was lower in children
who initiated ART after 2010 compared to those initiated between 2006 and 2009. Our findings
have important implications for programs implementing pediatric HIV care. The good long-term
survival is encouraging and should motivate early testing and treatment initiation in children.
Our findings also re-emphasize the need for early infant diagnosis; early treatment initiation and
close monitoring during the first six months of therapy as critical measures to reduce mortality of
children with HIV.
The overall 10-year survival probably in this study is similar to those reported in
other studies in sub-Saharan Africa 15, 24; however, they are lower than those reported in high
income countries 11, 12. The differences in survival are likely due to differences in quality of care
notably better patient monitoring and treatment regimens. We found children < 2 years had the
lowest 10-year survival probability (83%) and the risk of early death was higher in this age group
compared to older children (figure 2 &supplementary table 1). Poor survival in children <2 years
compared to older children has been reported previously 1, 3, 15, 24-33. The poor survival in these
children may be attributed to rapid disease progression in infancy 34, 35, while higher survival in
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older children may be attributed to survival bias. The children who initiated ART at older ages
are those who had survived through infancy without receiving ART, and some may be “longterm survivors” 36-38.
Half of the deaths in our study occurred during the first 6 months on ART [mortality rate
9.17 (95% CI: 8.55-9.84) deaths per 100 PY]. In addition to age <2 years, the other factors
associated with a higher risk of death within the first six months were WHO stage 3 or 4, severe
immune suppression and underweight, which are all markers of severe HIV disease. These
findings imply these children initiated ART late. These findings, which have been reported in
other studies 1, 3, 15, 25-30, highlight two important needs that should be addressed in order to
mitigate early mortality in children with HIV. First, there is a need for continued efforts to
diagnose and treat HIV in children early. Early diagnosis and treatment (within three months of
birth) reduce mortality in infants by about 75% 39. Access to early testing is still a challenge in
Eastern and Southern Africa. In 2017, only half of the HIV-exposed children in the study
countries received a virological HIV test within 2-months of birth 40. Improving retention of
mother-infant pairs in the postnatal period, integrating early infant diagnosis in child survival
platforms like immunization programs and expanding access to the point of care testing could
improve early testing. The current WHO treatment guidelines, which recommend initiating ART
upon diagnosis irrespective of disease severity 5, provide an opportunity to initiate treatment
early. Early treatment will only improve survival if the children are diagnosed early.
In addition to early infant diagnosis, the second need is for close monitoring of children
during the first 6-month period on ART and treating opportunistic infections. Although the WHO
recently provided guidance for treating patients with advanced HIV disease 21, specific guidance
for children under 5-year with advanced HIV disease was lacking. Updated data on frequent
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causes of morbidity and deaths among children with advanced HIV in RLS are needed and
intervention packages to reduce early mortality in these children may need to updated or
developed.
Encouragingly, we found that during the first two years on ART, mortality decreased
with increasing calendar period of ART initiation. In the multivariable analysis, the risk of death
in the first six months of ART was similar in children who initiated ART between 2010 and 2013
compared to those initiated in 2006-2017, but lower in those who initiated ART between 2014
and 2017. Among children who survived beyond 6 months, the risk of death was lower in those
who initiated ART in 2010 and beyond compared to those who initiated ART between 20062009 (table 2). This finding is unlikely due to better regimens and current guideline changes
because regimens and disease severity characteristics were controlled for in the analysis. The
finding may, therefore, represent a general improvement in care for children as health workers
become better trained and more confident treating children with HIV, and use of better
monitoring strategies, e.g., using viral load which has been associated with better survival. Since
2014, the studies sites have used viral load measurements to monitor treatment progress in
children. Additionally, the reduced risk of death after 2010 may also be due to the general
temporal improvements in survival in all children observed in the study countries 41.
The major strength of our study is that it is one of the few multi-country studies in subSaharan African that provides age-specific 10-year survival estimates of children receiving ART.
This allowed us to evaluate the impact of routine treatment programs on the survival of children
with HIV. Also, we were able to examine calendar periods that cover the most recent treatment
guidelines.
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Our study also has several limitations. First, up to 9% of our patients were LTFU, and
there is a possibility of informative censoring due to loss to follow-up which would lead to
underestimation of mortality. However, our sensitivity analysis treating loss to follow-up as a
competing risk found similar results showing that our findings are robust. Second, we do not
report causes of death; this is unfortunate as it would be helpful to guide intervention to reduce
mortality. In RLS, causes of death are not well documented. Third, we used CDC growth
standards to determine WAZ scores in children 10-14 years; this may have resulted in an
overestimation of underweight in these children since the CDC growth standards are mainly
based on measurement of growth in children in high-income countries. Lastly, our study was
conducted in COEs, which have higher standards of care than the general population; thus, our
mortality estimates may underestimate the mortality rates in children on ART.
Despite these limitations, our study findings are important for improving survival in
children. The finding that long-term survival in children is good should motivate the caretakers
of at-risk children to test them for HIV and to start ART immediately upon diagnosis. Prognostic
information is important for developing interventions to reduce early mortality. In addition, the
data on age-specific long term survival on ART could be used to model pediatric HIV
epidemiological estimates and life expectancy in children receiving ART. Lastly, our findings
will also provide a benchmark against which future intervention and guidelines will be measured.

CONCLUSION
Our study shows that overall 10-year survival in children receiving ART is good but
varies by age group. Mortality rates are highest in children aged < 2years and during the first six
months of ART. Disease severity characteristics were associated with a higher risk of early
mortality, and children who initiated ART after 2010 had a lower risk of mortality than those
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who initiated before. In order to improve survival in children with HIV receiving ART, problems
of late diagnosis and late treatment initiation should be addressed and close patient monitoring in
the first six months of care should be emphasized.
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ABSTRACT
Introduction
Although rapid ART initiation (initiating ART within 7-days of diagnosis) is associated with better survival,
retention and viral suppression in adults, data on these benefits in children are limited. We examined the
association between rapid ART initiation (same-day or 2-7 days versus 8-90 days from entry into care) in
children and 24-month all-cause mortality or loss to follow-up (LTFU).
Methods
We retrospectively analyzed data of HIV-infected children who initiated ART between 2014-2017 at seven
Baylor International Pediatric AIDS Initiative clinics in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and
Uganda. We defined LTFU as having a gap of 90 days between the next clinic appointment and the database
closure date (December 31, 2017). Follow-up time accrued from the ART initiation date to the earliest of
LTFU, death, transfer out, 24 months of follow-up or the database closure date. We assessed the association
between rapid ART initiation, and mortality or LTFU using the Fine and Gray’s sub-distribution hazard
regression for competing risks, adjusting for known risk factors of mortality and LTFU.
Results
Of the 3,299 participants, 1,516 (46%) initiated ART within 8-90 days of entry into care, 1004 (20%)
initiated ART within 2-7 days and 872 (24%) initiated ART on the same-day. Forty percent of the children
were aged <2 years, and half were girls. Overall, 254 (7.7%) died, 306 (9.3%) children were LTFU, 315
(9.6%) transferred care to another clinic and 2424 (73.5%) remained in care. The risk of mortality was
similar between children who initiated ART on the same-day [adjusted sub distributional hazard risk (aSHR)
=1.10, 95% CI 0.79, 1.75] and those who initiated within 2-7 days (aSHR=1.05, 95% CI 0.77, 1.43)
compared to those who initiated within 8-90 days. The risk of LTFU was higher in children who initiated
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ART on the same day (aSHR=1.86, 95% CI 1.39, 2.49) and those who initiated within 2-7 days (aSHR=1.83,
95% CI 1.38, 2.43) compared to those who initiated within 8-90 days.
Conclusion
Rapid ART initiation in children is associated with an increased risk of LTFU but not mortality. This data
suggest that rapid ART initiation in children is feasible but loss to follow-up should be addressed.
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INTRODUCTION
In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) set ambitious targets described
as “95-95-95” targets to end AIDS by 2030 1. These targets are that 95% of people living with HIV know
their HIV status, 95% of those diagnosed with HIV initiate and sustain ART and 95% of those on ART
achieve and maintain viral suppression. To attain these targets, children diagnosed with HIV must be linked
to HIV care, promptly initiated on ART and retained in care. However, 20% of children with HIV are lost to
follow up between diagnosis and ART initiation 2. After initiating ART, mortality ranges from 4.3-29% 3-6
and loss to follow-up (LTFU) ranges from 2-39% 6-10. These high losses to follow-up and mortality, if not
addressed, can preclude attainment of the 95-95-95 goals for children by 2030.
As a strategy to reduce loss to follow-up and mortality in people living with HIV, the World Health
Organization in 2017 recommended initiating ART in all people with HIV within 7-days (including sameday initiation in people who are ready) upon diagnosis and clinical assessment.11. This accelerated ART
initiation also called rapid ART initiation. This recommendation for rapid ART initiation followed a
systematic review of evidence from trials in adults that showed rapid ART initiation was associated with an
increased likelihood of starting ART, reduced mortality, and better viral suppression and retention in care as
compared to delayed initiation.12
Although the WHO recommended rapid ART initiation in children as well, data on the effect of rapid
ART initiation on outcomes of children were limited. Two trials conducted among hospitalized children
showed no difference in mortality in children who initiated ART rapidly versus those on delayed initiation 13,
14

. These studies do not include children who are not severely ill, and they do not examine if rapid ART

initiation is associated with loss to follow-up, yet, observational studies in adults show an increased risk of
being lost to follow-up after rapid ART initiation compared to delayed ART initiation 15, 16.
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Given the paucity of data on this topic in children, we examined whether rapid ART initiation was
associated with mortality and loss to follow-up in a cohort of children with HIV who initiated ART between
2014 and 2017 at Baylor International Pediatric AIDS Initiative (BIPAI) centers of excellence (COE) in six
African countries.

METHODS
Study design
We conducted a retrospective cohort study using electronic medical records of children with HIV,
who initiated ART at seven BIPAI COEs in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda.
The study was approved by ethics committees and institutional review boards in each country, Baylor
College of Medicine, and University of Texas Health Science Centre at Houston.
Study setting and treatment program.
The BIPAI COEs, which were started in partnership with respective governments, provide free
HIV/AIDS treatment and prevention services to children and adolescents. In 2014 and June 2016, all the
COEs except Uganda implemented 2013 WHO guidelines which recommended initiating ART in all
children aged <5 years irrespective of disease severity. Children aged 5-14 years were initiated if they have
stage 3 or 4 disease or CD4 count <500 cells/mm3. After June 2016, they updated the guidelines upon 2015
WHO recommendations to initiate ART in all children <15 years irrespective of disease severity. Uganda
implemented the guidelines to initiate ART in all children <15 years irrespective of disease severity from
2014.
At the COEs, caretakers of children receive pre-ART adherence counseling before initiating the
children on ART. Older children and adolescents, who are disclosed to and know their HIV status, usually
participate in the counseling session. Those who are ready to initiate ART receive medication on the same
day, while those who are not ready are given an appointment within seven days for another session and are

95

then initiated if ready. If the client is not ready after 7-days, the next appointment is given within the next
month on a mutually agreed date. Patients who do not return for appointments are tracked. After ART
initiation, the children are reviewed at two weeks, at one month and after that 3-monthly if they are
medically stable. Shorter appointments are given if medically indicated or if more psychosocial support and
counseling are required.
Study participants and data collection
We included ART-naive HIV-infected children aged <15 years who entered HIV care at the study
sites between January 2014 and 2017 and initiated ART within 90 days of enrollment. Ninety days was the
median time to ART initiation observed among patients diagnosed at enrollment in a global study of access
to ART in children 2. However, we also assumed that if children were eligible at enrollment, ART should be
initiated at most within 90-days. We excluded children who initiated ART less than 6-months from the
database closure date (December 31, 2017). The individual patient data were pooled electronically,
anonymized and transferred to the research team for cleaning and management.
Variables and definitions
Exposure: The exposure was the timing of ART initiation, which we categorized into same-day initiation, 27 days and 8-90 days. ART initiation on the same-day and within 2-7 days are defined by WHO as rapid
ART initiation 11. In our analysis, the reference group for comparison was those who initiated ART within 890 days.
Outcome: The outcomes of the study were all-cause mortality and loss to follow-up (LTFU). LTFU was
defined as having a gap of 90 days between the next clinic appointment and the database closure date
(December 31, 2017). The date of LTFU was the date the patient chart was closed in the EMR, and if the
chart was not closed, the patient was censored 90 days after the last scheduled appointment. Censoring
events were transferred out and active in care. The date of death and transfer out were the dates recorded in
the EMR, and if missing, the date the chart was closed in the EMR was used. Children were considered
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active in care if none of the other outcomes had occurred and they were assigned the date of the last visit as
the outcome date.
Other covariates: Other covariates considered were age, sex, country World Bank income category (middle
income vs. low income), weight for age Z-scores (WAZ), TB diagnosis, WHO clinical disease stage (WHO
stage) and immune suppression level and period of initiation (2014-2015 versus 2015-2016). The WAZ was
computed from the weight taken on the ART start date. If weights were missing, weight taken ± 1month
from ART start date was used. WAZ for children aged < 10 years were computed using the WHO child
growth standards 17, 18 and for children 10-14 years using the Centers for Diseases Control and Prevention
(CDC) growth standards 19. The CDC growth standards were used for children aged 10-14 years because this
measure was not available in the WHO growth standards. CD4 counts or CD4 percentage cut were
categorized into immune suppression level (no/mild, moderate or severe) for age according to the WHO
classification 11, 20. The year of initiation was categorized as 2014-2015 and 2016-2017.
Data analysis
Baseline characteristics at ART initiation were summarized using frequencies and proportions for categorical
variables, and medians and interquartile ranges (IQR) for continuous variables, stratified by the timing of
ART initiation. We considered death and LTFU as competing risks events and estimated the 24-month
cumulative incidence probabilities by the timing of ART initiation using competing risks survival analysis2123

. Follow-up time accrued from the ART initiation date to the earliest of LTFU, death, transfer out, 24

months of follow-up or the database closure date (December 31, 2017). We assessed the association between
rapid ART initiation and 24-months’ mortality and LTFU using the Fine and Gray’s sub-distribution hazard
regression model for competing risks adjusting for covariates21. Covariates were selected using stepwise
regression setting the criteria for a variable to enter and stay in the model at p=0.15 and p=0.05, respectively.
Known risk factors of mortality and LTFU were purposefully included in the mortality and LTFU analysis
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respectively. We imputed missing CD4, WHO clinical stage, WAZ, and hemoglobin values using multiple
imputation by chained equations (MICE), using 20 cycles 24, 25.

RESULTS
Characteristics at study participants at ART initiation
A total of 5,919 children enrolled in HIV care during the study period, of whom 5,483 initiated ART.
Of these, we excluded 18 children who were ≥15 years at ART initiation, 1,426 who were not ART naïve at
enrollment, 397 who initiated ART <6 months before the end of the observation period, 213 who initiated
ART after 90 days and 107 had only one medical visit. Patients who initiated ART after 90 days had less
advanced HIV/AIDS than those who initiated ART in less than 90-days (data not shown). The available
sample size after all exclusions was 3,299 participants (Figure 1). Among the 107 children had only one
visit, of whom 93 (86.9%) were initiated on the same-day, 8 (7.5%) within 2-7 days and six (5.6%) within 890 days. Upon tracking, 47 (44%) had died, five (4.6%) had self-transferred out, and 55 (51.6%) were lost to
follow-up (results not shown). Those who died, died within 5-days of initiating ART.
Table 1 describes the characteristics of the study participants stratified by the timing of ART
initiation. Of the 3,299 participants, the majority 1,516 (46%) initiated ART within 8-90 days of entry into
care, 1004 (20%) initiated ART within 2-7 days and 872 (24%) initiated ART on the same-day they enrolled
into care. Forty percent of the children were aged <2 years, half were girls and the majority were from lowincome countries. WHO clinical stage was similar across the strata with nearly equal distribution of children
with stage 1/2 and stage 4 disease. About 23.8% of patients had missing immune suppression (CD4) data.
The proportion of missing data was highest in those who initiated ART on the same day (40.7%). This is no
surprise since the guidelines in 2013 recommended immediate ART for all children <5 years and in 2015, all
children <15 years irrespective of CD4 count, so pre-ART CD4 tests were no longer mandatory.
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During 57,153 person-months, 254 (7.7%) died, 306 (9.3%) children were LTFU, 315 (9.6%)
transferred care to another clinic and 2424 (73.5%) remained in care.
Fig 1. Flow diagram of the inclusion criteria of the children with aged <15 years in the study and outcomes
in each stratum of ART.

Enrolled in HIV care between 2014 and 2017
N=5,901
Did not initiate ART, n=436
Initiated ART
N=5,465
Age at ART start ≥15years, n=18
Not ART-naive at enrolment, n=1,426

ART_naive and aged <15 years at ART initiation
N=4,021
Started ART<6 month before closing database, n=397
Time from enrolment to ART initiation >90days, n=218
One medical visit, n=107
Total included in analysis
N=3299

Same day initiation
N=779(24%)

1-7 days
N=1,004 (30%)

8-90 days
N=1,516 (46%)

Outcomes at 24months,n(%)
Active in care
535(66.7)
Died
65(8.3)
Lost to follow-up 101(13.0)
Transferred out
78(10.0)

Outcomes at 24months,n(%)
Active in care
735(73.2)
Died
79(7.9)
Lost to follow-up
117(11.7)
Transferred out
73(7.3)

Outcomes at 24months,n(%)
Active in care
2424(73.5)
Died
254(7.7)
Lost to follow-up
306(9.3)
Transferred out
315(9.6)
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Table 1: Baseline characteristics of participants at ART initiation.
Characteristic

same-day initiation
N=779

2-7 days
N=1004

8-90 days
N=1516

Total
N=3299

369(47.4)
138(17.7)
159(20.4)
113(14.5)

347(34.6)
253(25.2)
246(24.5)
158(15.7)

597(39.4)
285(18.8)
309(20.4)
325(21.4)

1313(39.8)
676(20.5)
714(21.6)
596(18.1)

415(53.3)
364(46.7)

523(52.1)
481(47.9)

754(49.7)
762(50.3)

1692(51.3)
1607(48.7)

285(36.6)
142(18.2)
286(36.7)
66(8.5)

367(36.6)
197(19.6)
436(43.4)
4(0.4)

597(39.4)
363(23.9)
540(35.6)
16(1.1)

1249(37.9)
702(21.3)
1262(38.2)
86(2.6)

10.7(9.3-11.9)

10.9(9.5-12)

10.8(9.5-12)

10.8(9.4-12)

None/mild
Advanced
Severe
missing
Underweight, n (%)

246(31.6)
82(10.5)
134(17.2)
317(40.7)

509(50.7)
93(9.3)
219(21.8)
183(18.2)

714(47.1)
198(13.1)
320(21.1)
284(18.7)

1469(44.5)
373(11.3)
673(20.4)
784(23.8)

None/mild
mod
Severe
missing
ART regimen, n (%)

328(42.1)
156(20)
292(37.5)
3(0.4)

450(44.8)
239(23.8)
314(31.3)
1(0.1)

715(47.2)
319(21)
482(31.8)
0(0)

1493(45.3)
714(21.6)
1088(33)
4(0.1)

NNRTI based
PI- based/other
Period of ART start
2014-2015
2016-2017
WB Income level
Middle income
Low income

443(56.9)
336(43.1)

706(70.3)
298(29.7)

1013(66.8)
503(33.2)

2162(65.5)
1137(34.5)

344(44.2)
435(55.8)

666(66.3)
338(33.7)

1019(67.2)
497(32.8)

2029(61.5)
1270(38.5)

122(5.7)
657(94.3)

57(5.7)
947(94.3)

535(35.3)
981(64.7)

714(21.6)
2585(78.4)

Age n (%)
<2 year
2-4 years
5-9 years
10-14 years
Sex, n (%)
Female
Male
WHO clinical stage, n (%)
1&2
3
4
missing
Haemoglobin(mg/dl)
median(IQR)
Immune suppression, n (%)

§ ART- antiretroviral therapy ‡ WB- World Bank
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Timing of ART initiation and the risk of mortality and loss to follow-up
There was a difference in risk of mortality between rapid ART initiation and delayed initiation;
however, the rapid ART initiation was associated with a higher risk of LTFU than delayed initiation. There
was no difference in the 24-months cumulative incidence (CI) of mortality by timing of ART: same day
initiation CI=9.9%, 95%CI 7.7%, 12.5%); 2-7 days CI=8.3%, 95% CI 6.7%, 10.2%, and 8-90 days CI=7.9%,
95% CI 6.5%, 9.4%; p<0.4. The 24-month risk of mortality was similar between those who initiated ART on
the same day or within 2-7 days compared to those who initiated ART within 8-90 days of entering care after
adjusting for other risk factors (table 2).
The 24-months cumulative incidence of LTFU was higher in children initiated on the same-day of
entering care (16.3%, 95% CI 13.4%-19.5%) and those initiated within 2-7 days (13.3%, 95% CI 11.1%15.7%) compared to those initiated within 8-90 days (6.8%, 95% CI 5.5%-8.3%), p<0.001 (Figure 1b). The
adjusted hazard risk of LTFU was higher in children initiated on the same-day and in those initiated within
2-7 days compared to those initiated within 8-90 days (table 2). Compared to children initiated on ART
within 8-90 days, the risk of LTFU in those initiated on the same-day was 1.86 times higher (aSHR=1.86,
95% CI 1.39, 2.49) and the risk in those initiated within 2-7 days was 1.83 times higher (aSHR=1.83, 95%
CI 1.38, 2.43).
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Figure 2a

Figure 2b

Figure 2: The cumulative incidence of mortality (figure 1a) and loss to follow-up (figure 1b), by the timing
of ART initiation among HIV infected children initiated on ART between 2014-2017 at BIPAI COEs in 6
African countries
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Table 2: Unadjusted and Adjusted all-cause mortality and loss to follow-up sub-distributional hazard
ratios for the first two years of antiretroviral therapy, by the timing of ART.
Timing of ART

Events
(n/N)

Unadjusted
sHR
95%CI

CIF (%) 95%CI

Adjusted§
sHR
95% CI

Mortality
8-90 days
2-7 days
same-day

110/
79/
65/

7.85
8.32
9.91

8-90 days
2-7 days
same-day

88/
117/
101/

6.83
13.29
16.32

6.5, 9.35
1
6.67, 10.2
1.09
0.81, 1.45
7.67, 12.49
1.21
0.89, 1.65
Loss to follow-up all children
1
5.52, 8.31
11.12, 15.66
2.05
1.56, 2.71
13.43, 19.47
2.60
1.95, 3.45

1
1.05
1.10

0.77, 1.43
0.79, 1.54

1
1.83
1.86

1.38, 2.43
1.39, 2.49

§

Adjusted for age, immune suppressions, hemoglobin level, period of ART initiation and country income level. WHO clinical
stage was adjusted for in mortality analysis only; ‡ Sensitivity analysis was conducted among patients who had 2 or more visits
(N=3299). CIF- cumulative incidence function

DISCUSSION
In this study of 3,299 HIV-infected children aged <15 years who initiated ART between 2014 and
2017 at BIPAI COEs in 6 African countries, we found that in the first 24-months of ART, rapid ART
initiation was associated with higher loss to follow-up but was not associated with mortality. Given the need
to initiate ART early in children, our findings suggest that rapid ART initiation could be implemented
without impacting mortality of children, but loss to follow-up should be addressed
We found that rapid ART initiation (same-day and within 2-7 days) was associated with higher
LTFU compared to initiation within 8-90 days even after excluding children who had only one visit after
initiating ART. Similar findings have been reported in observational studies among pregnant women with
HIV who initiated ART on the same day as diagnosis 15, 16. In contrast, our previous study in public health
facilities in Uganda found no difference in retention among children initiated on the same day and those in
whom ART was delayed 26. However, our previous study was underpowered to detect a difference in
retention between the groups; thus, the finding was inconclusive. Although reasons why children who
initiated ART on the same-day drop out of care are not well understood, a plausible reason is that the
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caregivers of children initiated on the same-day were not ready but chose to accept either because it was
offered or because they felt pressured by providers to start, and they dropped-off after starting. Lack of
readiness to start and feeling pressured by providers to start ART on the same day has been reported as a
reason for dropping off from care among adults 16, 27, 28. Caretakers of children may require time to reflect on
the HIV-diagnosis in the child, the implications of life-long treatment and the need to disclose to their
partner if they have not.
We did not find an association between rapid ART initiation and mortality. This finding confirms
findings from previous clinical trials conducted among hospitalized children 14, 29. Although these trials and
our study report no association between rapid ART initiation and mortality, we found much lower mortality
(9.9%) among children who initiated ART on the same-day compared to the mortality among children who
initiated ART within 48hrs in the Kenyan trial (23%). This difference is because the Kenyan study was
conducted among Hospitalized children while ours was among a combination of both ill and relatively
healthy children. Although, the purpose for immediate ART initiation is to maximize benefits of ART in
children, not observing higher mortality in the children who initiated ART within a week is a reassurance
that it does not harm. Additional, half of the children initiated ART within a week, meaning that it is
acceptable and is feasible to implement without. Other benefits of same-day initiation observed in clinical
trials in adults that should be investigated in children include reduced time to viral suppression and reduce
pre-ART loss to follow-up. 30-32
We excluded children who had one visit after initiating ART on the assumption that they never
established care. On further analysis, we found these children had higher odds of having advanced disease
and those who died, died within 5-days of initiating therapy. Although we could not confirm, it is possible
that these children were ill and possibility hospitalized. It is also possible that they would have died even if
ART were not initiated. The WHO guidelines recommend that in ill children, management of acute
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conditions should be prioritized over ART initiation 11. More work, however, is required to understand which
children do not return to care after rapid initiation and why they do not return into care. Theory-based should
be used to understand the underlying determinant of loss to follow up and develop evidence-based
interventions to reduce loss to follow-up. Such approaches include intervention-mapping approach 33
Several limitations need to be considered when interpreting our findings. First, patients reported as
lost to follow-up may have died and were misclassified as LTFU. Our findings may, therefore, underestimate
mortality. However, we are not certain if this bias would be differential or non-differential. Second, our
analysis of LTFU did not control for structural and psychosocial determinants of loss to follow-up like the
distance traveled to the clinic, and hence there is potential for residual confounding; however, we cannot
determine the direction. Third, we excluded patients who initiated ART after 90 days of enrolling into care.
These patients were relatively healthy at ART start, and by excluding them from the reference group, we
may have overestimated mortality in the patients who delayed ART initiation, thus biasing our mortality
estimates towards the null. However, this group represented only 6% of the population, previous global
analysis of time to ART found a median initiation time to ART of 1 month 2 and as programs implement
ART guidelines 34, time to ART will be shorter; thus, our cut off time of 90 days is reasonable. Lastly, we
excluded patients who had only one visit. These patients had higher odds of advanced disease; most had been
initiated on the same day and those who died, died within five days. We may have underestimated mortality
among those who initiated ART on the same day; however, given that most of these patients died within five
days, we assumed they had not established HIV care
Notwithstanding the limitations, findings from our study, which is conducted in a programmatic
setting, have important implications for the implementation of the universal ART and rapid ART initiation
guidelines in children. These findings suggest that in programmatic settings, it is feasible to implement rapid
ART initiation in children; however, loss to follow should be addressed. To attain better outcomes in
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children during the implementation of rapid ART initiation, ART initiation protocols that incorporate rapid
diagnostic assessment, readiness assessment, and retention strategies should be developed and tested in
programmatic settings. Because in untreated children HIV progression is fast and mortality is high 35-37, care
should be taken not to over-delay ART in children and miss the benefits of ART. If the rapid ART initiation
guidelines are implemented without approaches to reduced mortality and loss to follow-up, attaining the 9595-95 goals for children in 2030 may be elusive.

CONCLUSION
Our study shows that in the first 24-months of ART, rapid ART initiation is associated with worse
loss to follow-up but did not affect mortality in children aged <15 years. Our findings suggest that rapid
ART initiation in children is feasible, but loss to follow-up needs to be addressed. More research is required
to develop approaches and models for implementing rapid ART initiation in children while maintaining good
outcomes for children.
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CONCLUSIONS
In these three studies conducted among HIV infected children (0-14 years) who initiated
ART between 2003-2017 at seven Baylor International Pediatric AIDS Initiative centers of
excellence in 6 Eastern and Southern African countries, we have described age- and site-specific
trends in advanced disease at ART initiation. We also described 10-years survival and risk
factors of early mortality and examined the association between rapid ART initiation and
outcomes of HIV infected.
We found that the between 2003-2017, trends proportion of children with advanced HIV
disease at ART initiation varied age group and country. The proportion declined in children aged
5-14 years, remained the same in those aged <2 years and increased slightly in those age 2-4
years. We also found that over time children initiating ART in southern Africa sites were older
and less severely ill, while those in Eastern Africa sites were younger and more severely ill. In
addition, at the end of the observation period (2016-2017), most children initiated ART within
one week of entry into care, but a substantial proportion initiated ART with advanced disease.
Our study also found that about 88.9% of children with HIV will be alive ten years after starting
ART, but survival was lower in children < 2years (83%). We also established that 50% of the
deaths were within six months of starting therapy and that young age (<2 years), advanced HIV
disease and being underweight were associated with advanced HIV disease. Lastly, we found
that rapid ART initiation in children was independently associated with a higher risk of loss to
follow-up after 24-months of ART but was not associated with mortality.
Our findings have important implications for pediatric HIV prevention, care and treatment
programs. First, our findings re-emphasize the need for more efforts to diagnose and initiate
children on ART early, and the need to closely monitor children during the first 6-months of
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ART as measures to reduce mortality in children with HIV. Our finding that long-term survival
in children is good should motivate the caretakers of at-risk children to test them for HIV and to
start ART immediately upon diagnosis. Additionally, the data on age-specific long-term survival
on ART could be used to model pediatric HIV epidemiological estimates and life expectancy in
children receiving ART. Prognostic information can guide the development of interventions to
reduce early mortality. Lastly, our study shows that rapid ART initiation can be implemented in
children, but the high loss to follow-up should be addressed.
As mentioned in our papers, the strength of our studies was the use of large dataset from
multiple countries and spanning 5-periods of implementation of different WHO guidelines. This
enable used to compared trends and outcomes across countries and different guideline
implementation periods. In addition, our study also examines age-specific trends in advanced
disease and long-term survival, and this enabled us to show how pediatric HIV program
implementation and guidelines have differentially affected outcomes of different age groups of
children. Our studies also had weaknesses that should be considered when interpreting our
findings. First, the generalizability of our findings should be treated with caution because our
study sites are well resourced, better staffed and likely to have a higher quality of care than
public health facilities. However, in some countries like Botswana, our the study site provide
care to nearly a third of all children in the country, and this enhances generalizability. Second, as
with most observational data, we had missing data for important variables; however, to avoid
loss to information, we imputed missing values. Third, in some of our analysis, there was
potential for informative censoring due to loss to follow-up, but we conducted sensitivity
analysis in one analysis that showed our results were robust and used competing risks analysis in
other to address informative censoring. Lastly, in our analysis of the association between rapid
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ART initiation and loss to follow-up, we did not adjust to structural and psychosocial
determinants of loss to follow-up, which could have led to residual confounding.
Future studies are required to identify interventions to reduce early mortality and loss to
follow-up in children with HIV especially in the current era of “treat all” guidelines and rapid
ART initiation. Such interventions should be theory-based and should focus on identifying and
addressing health systems changes and individual behaviors required to improve implementation
of pediatric HIV programs and improving outcomes. While the specific focus should be on
pediatric HIV, the interventions should have far-reaching benefits, for example, improving
systems for delivery of child survival interventions as a whole.
In conclusion, although we show that long-term survival is HIV-infected children treated
with ART is relatively good, children are still being diagnosed late and starting treatment late,
early mortality is high, and a significant proportion is lost to follow-up. While programs can use
the good survival outcome to motivate caretaker to test and initiate ART early in children, more
work is required to diagnose, initiate and keep children with HIV in care if we are to achieve the
95-95-95 goals by 2030.
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